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ABSTRACT 
 
 
This dissertation examines an individual’s perceived health status, and health 
values, as influences on self-initiated health action, specifically the pursuit of Direct-to-
consumer (DTC) genome testing.  Motivation for this independent health action may also 
have implications for other individual health behaviors, including the potential for 
positive changes that are lasting rather than temporary.  Health Capability, the conceptual 
framework, supports individual health values and goals, ability to access valued 
healthcare services and includes measures of health status.  However, Health Capability 
lacks an operationalized mapping of its major concepts.  This dissertation proposes and 
evaluates an original concept mapping and relationships.  
An overview of this dissertation and components is presented in Chapter one.  
Chapter two addresses the genomics and healthcare landscape related to independent 
individual pursuit of Direct-to-consumer (DTC) genome testing.  The Health Capability 
framework is initially presented in this chapter, together with the research hypotheses, 
targeted literature review of key concepts and the proposed concept mapping with 
relationships.  Chapter three describes the Health Capability conceptual framework, its 
adaptation and extension for the dissertation and its potential for use in health promotion 
and prevention research.  A systematic review of the literature on perceived health status 
is discussed in chapter four, as well as a targeted review of approaches to concept 
measurement and most commonly used instruments.   
Chapter Five presents the dissertation study.  This research involves 1455 self-
initiated Direct-to-consumer (DTC) genome testing users who represent a naturally 
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occurring phenomenon and provide a unique population to study the impact of an 
individual’s subjective perceived health status, personal health values and health goals.  
Participants completed surveys as part of the Impact of Personal Genomics (PGen) study.  
These participants were classified into four mutually exclusive health status groups based 
on individual perception of health and a healthcare system perspective of health status 
(existence of a medical diagnosis).  These groups were analyzed for the following:  1) 
discrepancies in health status, 2) differences in reasons for genome testing, perceived risk 
and health values, and 3) potential relationships among variables.  Results confirmed 
discrepancies between individual and biomedical health status.  One group may represent 
the “worried well”.  Interest in health information was high (98–99%) across all groups, 
as was health value of genome test results.  Two items distinguished all groups (interest 
in pharmacogenomics information and learning risk for other diseases (p < .001).  When 
groups differed, perceived rather than biomedical health status was often involved, yet 
both factors demonstrated influences (variable dependent).  Risk perception was 
moderately correlated (.301) with health status group, yet clearly does not equate with 
perceived health.  Persons with medical diagnoses and self-rated not good health scored 
highest for items relating to immediate personal health and for family.  Study findings are 
consistent with individual perceived health status and health values as significant factors 
influencing self-initiated health action (DTC genome testing).   
Chapter six further interprets research results as they relate to the hypotheses and 
to future research plans.  Implications of the study results for revision and extension of 
the Health Capability concept mapping and framework are also discussed.  These 
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include: 1) supporting health status and values as principle concepts; 2) supporting 
addition of a measure of individual (subjective) perceived health status; 3) representing 
resources outside the healthcare system; and, 4) exploring the possibility of a personal 
need or value, as a “trigger” to action.  These are areas of planned further research 
relevant to personalized healthcare, effective clinical practice, a collaborative healthcare 
model and meaningful policy development. 
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CHAPTER I 
 
INTRODUCTION & PURPOSE OF THE RESEARCH 
 
 
Background 
 
An estimated one million persons have self-initiated Direct-to-Consumer (DTC) 
genome testing touted for its abilities to identify potential health risks and ancestral 
heritage (Genetics & Public Policy Center, 2011; Wojcicki, 2013).  Users of this testing 
span adults of all ages, with health status varying from having medical diagnoses to 
healthy persons.  Why do consumers want and pursue this testing despite cautions about 
its limitations and the potential harms if results are misinterpreted (American College of 
Medical Genetics and Genomics, 2013; American College of Medical Genetics and 
Genomics (ACMG), 2012; Clarke, 2013; Hesse, Arora, & Khoury, 2012)?  DTC studies 
to date of individuals’ motivations have limitations and leave many questions 
unanswered (Bloss, Darst, Topol, & Schork, 2011; Facio et al., 2011; Goldsmith, 
Jackson, O'Connor, & Skirton, 2012; Gollust et al., 2011; D. J. Kaufman, Bollinger, 
Dvoskin, & Scott, 2012).  Akin to studies of mortality and morbidity where self-rated 
health status was a predictor of health outcomes and reflected actual individual health 
(Idler & Benyamini, 1997; Miilunpalo, Vuori, Oja, Pasanen, & Urponen, 1997; Okosun, 
Choi, Matamoros, & Dever, 2001), does perceived health status as well as health values 
influence individual health needs, goals and motivations on a grander scale (and 
throughout the lifespan), regardless of health status or values as determined by healthcare 
system standards?  If so, this could and should change the face of healthcare.  
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From another perspective of this question, consider persons who present to their 
healthcare provider with health concerns yet have no diagnosable condition.  Are they the 
“worried well” (Garfield, 2006), are they cases illustrating discrepancies between health 
status as perceived by the individual versus healthcare system assessment criteria 
(Kivinen, Halonen, Eronen, & Nissinen, 1998; Okosun et al., 2001), and/or are they 
proactive prevention-oriented persons whose needs are not being met in the context of a 
disease-oriented biomedical model (Juengst, Settersten Jr, Fishman, & McGowan, 2012; 
Personalized Medicine Coalition, 2014)?  Are these various groups of persons also 
included among DTC genome testing users, hoping to get some answers or information 
important to their health functioning?  The purpose of the dissertation study is to examine 
individual perceived health status (in contrast to health status based on healthcare system 
criteria) and individual health values as factors that distinguish and influence (motivate) 
individual health needs, goals and actions in persons who independently pursue DTC 
genome testing. 
 
Overview and Integration of Chapters, Content and Study 
 
The background, current status, challenges and implications of genomic testing 
(including the DTC aspect) for individuals and the healthcare system are presented in 
Chapter II.  My unique research study (Chapter V) required exploration of a healthcare 
model that embodies study concepts and philosophy, bridges the gap between the 
traditional biomedical model and respect for individual health values and goals, allows 
for independent individual choices and actions (e.g., DTC genome testing), and supports 
examination of subjective individual health influences and new strategies for effective 
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healthcare services and health promotion.  The Health Capability conceptual framework 
(Ruger, 2010) fits these criteria and is described in Chapter III, which also presents an 
early version of the proposed conceptual process model (since this chapter represents an 
article submitted for journal publication in the Fall of 2013).  The current, detailed 
concept mapping proposal for operationalizing Health Capability, a need recognized by 
its author (Ruger, 2010), includes designation of relationships, corresponding hypotheses 
and concepts covered in literature review, and is explained in Chapter II.  A systematic 
review of the literature on perceived health status is described and discussed in Chapter 
IV, together with concept measurement approaches and instruments, unifying the Health 
Capability model (i.e., author’s suggested consideration of the SF-36 instrument), the 
research study (i.e., survey question used to capture this concept) and future potential 
research and practice applications.  The dissertation research study (Chapter V) examines 
health status from the unique perspective of combining an individual’s perceived health 
status (dichotomized) with a biomedical assignment of health status (presence/absence of 
diagnosis/es), thus creating mutually exclusive health status groups for analysis of 
differences related to subjective health factors (i.e., individual health values, 
reasons/motivations for testing, perception of health risk).  The study population is 1,455 
self-initiated DTC genome testing users who completed surveys as part of the large scale 
NIH funded Personalized Genomics (PGen) study (R. Green & Roberts, 2012b).  This 
sample represents a rare, naturally occurring virgin sample of persons who pursued 
broad-based health-related genome testing without a healthcare practitioners’ order or as 
part of an approved research study.   
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Results of this dissertation research have current and future substantive relevance 
to genome testing, healthcare models and health-related applications across individuals, 
populations, ages, ethnicities, and all clinical practices, as discussed in Chapter VI.  
Beyond the genomics context, this study offers real potential to gain new, previously 
unrecognized or misinterpreted, insights into subjective human factors and health values 
that may contribute to, or even trump, biomedical factors as influences on individual 
health-related needs, actions, receptivity to information and interventions, and 
implementation as well as endurance of health-related behaviors.  These factors are 
important to effective and efficient allocation, prioritizing and development of healthcare 
services, resources and policy.  
 
Objectives of the Dissertation 
 
Specific objectives of this study include the following:  
 
1) Representation of the realities and controversies of the genomic healthcare 
environment, genomic testing and motivations of Direct-to-Consumer (DTC) 
genome testing users (Chapter II); 
 
2) Identification and description of a healthcare conceptual framework (Health 
Capability), philosophically aligned with individual health values and goals, 
and compatible with examining personal factors influencing individual pursuit 
of genome testing (Chapters II and III); 
 
3) Development of a concept mapping for the Health Capability model to 
represent the principle concepts (including health status and health values, as 
described in the literature review), their proposed relationships, and added 
elements philosophically consistent with Health Capability and relevant to the 
dissertation research (i.e., access to resources outside the healthcare system, 
e.g., DTC laboratories) (Chapter II:  current concept mapping; Chapter III:  
earlier version as submitted with an article for publication); 
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4) Investigation of the concept of perceived health status, how it is defined and 
operationalized, and the nature, types, strengths and limitations of approaches 
and instruments used to measure, represent, interpret and apply this concept 
(Chapter IV); 
 
5) Description of the original research categorizing and characterizing DTC 
genome testing users by health status groups based on an individual’s 
perceived health versus a medical perspective of health status (Chapter V); 
 
6) Description and comparison of relationships/associations between health 
status categories of DTC users and the following:  1) reasons (motivations) for 
genome testing, 2) socio-demographic factors, 3) perception of health risk, 
and 4) health value of genomic information (Chapter V); 
 
7) Initial exploration to identify and present previously unknown individual 
reasons/motivations for pursuit of genome testing, based on answers to open 
text questions (Chapter V); 
 
8) Evaluation of research findings and dissertation processes, including 
suggested modifications related to Health Capability and the proposed concept 
mapping, strategy(s) for choice and use of perceived health status measures, 
and discussion of implications for clinical practice and future research 
(Chapter VI). 
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CHAPTER II 
 
GENOMICS HEALTHCARE ENVIRONMENT, CONCEPTUAL FRAMEWORK FOR 
RESEARCH AND LITERATURE REVIEW  
 
 
Background: The Genomics & Healthcare Environment 
 
Biomedical advances engendered by the Human Genome Project (HGP), 
spanning whole genome sequencing (WGS), evolving technology and bioinformatics, 
have opened new horizons for healthcare.  These include the following:  1) diagnosis of 
previously unknown or complex disorders (ACMG, 2012; Gahl et al., 2011); 2) 
assessment of common conditions such as cancer for risk, treatment and prognosis (e.g., 
colon cancer) (National Comprehensive Cancer Network (NCCN), 2014); 3) 
identification of pharmacogenetic variation important to drug therapy; risk screening for 
early identification, risk management and prevention (Botkin et al., 2010; Do et al., 2011; 
Kwon et al., 2010); and, 4) genome panels, e.g., related to neuromuscular and 
cardiovascular conditions (AmbryGenetics, 2012; Marian, 2012).  Genomic factors can 
now be identified in association with low but increased risk for complex and common 
disorders impacting large numbers of people (Offit, 2011).    
Genome testing offers a unique opportunity for personalized DNA-based health 
risk assessment with test results promising information potentially impacting individual 
health, risk management and prevention strategies (Berg, Khoury, & Evans, 2011).  
These capabilities, advances and potentials are not only published in the scientific 
literature, e.g., DTC testing that identified a previously unsuspected mutation having 
clinical significance (Personalized Medicine Coalition, 2011; M. E. Roberts, Riegert-
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Johnson, & Thomas, 2011), but are a daily part of mass media news (Grogan, 2014), 
online information (Landro, 2013), social networking, and marketing efforts (ScottH, 
2013) raising consumer awareness and interest in genome testing.  Genomic testing could 
conceivably be so powerful an influence as to transform medicine and healthcare (Evans 
& Green, 2009). 
 
Issues and Controversies:  Healthcare Model, Policies and Individuals 
 
Consistent with the biomedical model and healthcare policies, recommendations 
advise limiting whole genome testing to patients assessed by a healthcare provider, 
meeting eligibility criteria for a specific diagnosis or targeted genetic risk, and based on 
guidelines (American College of Medical Genetics and Genomics, 2013; American 
College of Medical Genetics and Genomics (ACMG), 2012; Botkin et al., 2010; Graves, 
Peshkin, Luta, Tuong, & Schwartz, 2011; Skirton, Goldsmith, Jackson, & O'Connor, 
2012).  Third party payers’ policies for genetic testing are limited, targeting specific 
conditions or approaches for medically justified exceptions.  Coverage does not include 
full genome testing for identification of risks (BlueCross BlueShield, 2014; 
UnitedHealthcare, 2014).  These professional guidelines and coverage policies reflect 
concerns for potential harms to patients, lack of evidence to support clinical benefit 
beyond targeted applications or that risk translates to disease, and decisions based on 
economic healthcare realities (e.g., limited resources).   
Consumers committed to genome testing must take the initiative to obtain this 
testing on their own.  Direct-to-Consumer (DTC) genomic testing (NHGRI, 2012) is 
available to anyone, without involvement of a licensed practitioner, via DTC labs and the 
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Internet (GPPC, 2011).  Until recently (May, 2014), despite Federal Drug Administration 
cautions and prohibitions (Gutierrez, 2013), a few DTC labs offered consumers health-
related genome testing and information (for as little as $99 at one lab that included 
interpretative reports and raw genomic data) (23andMe, 2014b), as an option among 
“packages” such as ancestry and paternity testing (Clarke, 2013; Hensley, 2013; Wagner, 
2013).  This latter lab stipulates that it no longer provides health reports at the present 
time (although raw genomic data is still generated).  The ultimate fate of individual DTC 
health-related genome testing, in general, is yet to be determined.  Individual independent 
use of DTC genome testing is highly controversial (Caulfield, 2011; Evans & Khoury, 
2013; R. C. Green & Farahany, 2014; Personalized Medicine Coalition, 2011).  Issues 
span healthcare, ethics and individual rights (Rivkin & Grossman, 2013), consumer 
knowledge and related needs (Hahn et al., 2010), public health, laboratory reporting of 
risk (Bloss, Topol, & Schork, 2012; Imai, Kricka, & Fortina, 2011), evidence (or lack) 
for action ability based on genomic profiles (Janssens et al., 2008; Janssens, Wilde, & 
van Langen, 2011), provider readiness for integration of genomics (Evans & Green, 
2009; Frueh, Greely, Green, Hogarth, & Siegel, 2011; Li, 2011; McBride et al., 2009), 
and gaps in policy, standards and regulatory arenas (Caulfield & McGuire, 2012; Frueh et 
al., 2011; Hauskeller, 2011; Kontos & Viswanath, 2011).  Meanwhile, evidence mounts 
supporting the unique value of genomic information and the integration of risk testing 
into health assessment and healthcare based on its potential for broader applications to 
health promotion (Ashley et al., 2010; Botkin et al., 2010; Korf, 2012; Manolio et al., 
2013).   
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Summary & Impact on Dissertation Study 
 
A definitive gap exists between what genome testing is authorized, regulated and 
deemed of clinical utility by the healthcare system (Palomaki et al., 2010) and is covered 
by insurance policies (Graf, Needham, Teed, & Brown, 2013), versus what is of possible 
individual value and personal utility (Bunnik, Schermer, & Janssens, 2011; Grosse, 
McBride, Evans, & Khoury, 2009), is/has been accessible via DTC laboratories (Genetics 
& Public Policy Center, 2011; Graf et al., 2013) and has some professional and advocacy 
group support (Caulfield, 2011; Personalized Medicine Coalition, 2014; The Lancet 
Editorial, 2012).  Although the consumers’ ability to obtain DTC health-related genomic 
testing in the future might appear to be diminishing (23andMe, 2014b; FDA, 2014; 
Gutierrez, 2014; National Human Genome Research Institute, 2014), the final policies are 
yet to be determined.  This is dependent upon not only U.S. FDA regulatory authority 
(National Human Genome Research Institute, 2014; Shuren, 2010; Wagner, 2013), but 
also policies in process, potential constitutional challenges (Rivkin & Grossman, 2013), 
and laboratory-related decisions at international levels.  This situation, however, does not 
change the very relevant questions posed in this dissertation research, nor more 
importantly, the broader knowledge that may be gained from this singular population and 
study of self-initiated DTC genome testing users.  
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Framing the Research:  Questions & Hypotheses 
 
Research Questions 
 
What motivates people to seek genome testing independent of their healthcare 
providers?  Why do they pursue this controversial testing?  Are they the “worried well” 
(Garfield, 2006), are they cases illustrating discrepancies between health status as 
perceived by individuals versus healthcare system assessment criteria (Kivinen et al., 
1998; Okosun et al., 2001) and/or are they proactive prevention-oriented persons whose 
needs are not met in the context of a disease-oriented biomedical model (Juengst et al., 
2012; Personalized Medicine Coalition, 2014)?   
Do individually perceived health status and individual health values impact 
health needs, motivations and actions in persons who independently pursue genomic 
testing and information, regardless of health status and values determined by healthcare 
system and biomedical criteria?  Is there personal health value to genomic information 
beyond bio-medically defined and determined use & value?   
 
Research Hypotheses (See Figure 2.1 for hypotheses and relationships) 
 
Hypothesis 1:  Discrepancies exist between an individual’s perceived general 
health status and health status as defined by healthcare system measures (existence of a 
medical diagnosis). 
Hypothesis 2 (null):  There will be no difference in motivation(s) for pursuit of 
genome testing between health status groups stratified by individual perception of health 
and healthcare system measures (existence of a medical diagnosis). 
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Hypothesis 3 (null):  There will be no difference in socio-demographic factors 
between health status groups stratified by individual perception of health and healthcare 
system measures (existence of a medical diagnosis). 
Hypothesis 4 (null):  There will be no difference in perception of risk between 
health status groups stratified by individual perception of health and healthcare system 
measures (existence of a medical diagnosis). 
Hypothesis 5 (null):  There will be no difference in health value of genomic 
information between health status groups stratified by individual perception of health and 
healthcare system measures (existence of a medical diagnosis). 
 
Research Rationale and Justification 
 
By categorizing health status as a combination of an individual’s perceived health 
and health status using healthcare system measures (i.e., existence of a medical 
diagnosis), and examining the identified subjective health-related variables, associations 
between health status groups and their distinguishing factors may be identified.  This 
study has the potential to contribute new knowledge and understanding about human 
motivations in seeking and using health-related services such as DTC, as well as 
impacting and committing to health-related behaviors, relevant to clinical practice and 
research.  The study findings may contribute to informing future strategies for screening 
and assessment, especially for individuals who challenge the healthcare system, such as 
the apparently healthy (e.g., the worried well, versus the early ill, versus the prevention-
oriented).  Implications, however, extend to other areas of identified need in healthcare.  
These include facilitating practitioner and individual discussions and decisions related to 
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individual health priorities (McGuire, Diaz, Wang, & Hilsenbeck, 2009), approaches to 
risk assessment and management, targeted interventions and options, effective allocation 
of healthcare services and resources (e.g., avoiding treatments, procedures and 
expenditures that do not have individual health value) (Ruger, 2010), and integrating 
measures for evaluation of healthcare services and outcomes relating to both clinical 
utility and personal utility since both impact services and policy development (Bunnik et 
al., 2011).  
The dissertation study’s unique dataset of 1,455 Personalized Genomics study 
survey respondents (R. Green & Roberts, 2012b), all who self-initiated DTC genomic 
testing, serve as a natural, uncontrolled population to learn about subjective individual 
factors potentially influencing independent pursuit and interest in using health-related 
testing and services (i.e., genomic testing), but also potentially contributing to informing 
and advancing healthcare in a broader realm, as noted above.  
 
Conceptual Framework:  Health Capability  
 
A healthcare model and conceptual framework is needed whose tenets 
acknowledge individual health values and goals, and include primary concepts of the 
current dissertation study.  This model must support inclusion of individual (subjective) 
criteria in determining health goal achievement, allow for individual access to health-
related resources beyond the traditional healthcare system, foster health promotion and 
prevention on an individual level, and define health values and successful outcomes by 
other than economic measures.  A model integrating these dimensions has been 
recommended previously (J. P. Sturmberg, O'Halloran, & Martin, 2012).  Given an 
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empowered public, evolving advances in bioinformatics and technology, a healthcare 
system expected to meet the health needs of individuals and the general public, and 
economic realities, any meaningful model must also be systems-oriented and supportive 
of communication, collaboration, shared responsibility in decision-making and policy 
development involving all stakeholders (Li, 2011; Joachim P Sturmberg, 2007).  
The Health Capability conceptual framework meets these stipulated criteria.  This 
healthcare model is discussed in detail in Chapter III.  In this chapter, a conceptual 
mapping (see Figure 2.1) is proposed, presented and discussed as the basis for organizing 
key concepts, representing their relationships and identifying the focus of the literature 
reviewed later in this chapter.  
 
Concepts, Relationships and Study Foci 
 
The principle tenets and concepts of the Health Capability conceptual framework 
include individual health values, health status and health functioning, and health goal 
achievement (Ruger, 2010) (see Figure 2.1).  Their relationships were not specified in the 
original conceptual framework, or subsequently.  Thus, consistent with current study 
hypotheses, these concepts are depicted as interrelated, being joined by a heavy solid line.  
A Health Capability profile provided the internal and external influencing factors (Ruger, 
2010).  The major categories of which are summarized in Table 2.1.  These internal and 
external factors are listed within overlapping hashed boxes in Figure 2.1, thus 
representing a postulated dynamic interplay.  The area within the red-hashed irregular 
borderline identifies the current study focus.  Solid blue lines represent connections  
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Table 2.1:  Health Capability Profile*:  Influencing Factors. 
 
INTERNAL EXTERNAL 
A. Health status & health functioning  A. Social norms 
B. Health Knowledge  B. Social networks and social capital 
C. Health seeking skills and beliefs, self-efficacy C. Group memberships  
D. Health values and goals D. Material circumstances 
E. Self-management; ability achieve health outcome E. Economic, political &social security 
F. Effective health decision-making F. Utilization/Access to health services 
G. Intrinsic motivation to achieve health outcomes G. Enabling public health & health sys 
H. Positive expectation: achieving health outcomes *Adapted from Ruger, 2010, p 45-46. 
 
between the concepts, factors or components that were identified by the author.  Hashed 
blue lines represent connections that include a factor or component proposed in my 
current study.  Hypotheses, denoted by an “H” and the hypothesis number, are in small 
red boxes positioned with the corresponding concepts and relationship.  Based on 
Hypothesis 1, the proposed influence of individual perceived health (highlighted in 
yellow in the text box in the left middle of Figure 2.1) has been added and connected by a 
blue-hashed line to Health Status.  Similar, for Hypothesis 4, the propose influence and 
connection between Health Status and Personal Measures of Risk (highlighted in yellow) 
is represented by a hashed line.  Hypothesis 2 and Hypothesis 5 are represented by solid 
lines between concepts and factors.  Hypothesis 3 represents an association between 
Health Status and components involving selected external factors (socio-demographic 
based on survey data).  Resources available outside the traditional healthcare system are 
represented as an extension (hashed line) of existing resources, on the right side of Figure 
2.1.  This component, specifically the DTC genome testing box, is not contained within a 
red-hashed border but instead is highlighted in blue (lower right of Figure 2.1) since it 
defines the primary eligibility criteria for study participants and identifies that all pursued 
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this route.  Study concepts, highlighted in yellow, are numbered and correspond to the 
literature review later in this chapter.  
 
Conceptual Framework Adaptations 
 
Two conceptual framework adaptations were done for this study for the purposes 
of operationalization and model extension (i.e., genomics and prevention).  First, health 
status and health functioning, represented in Health Capability collectively as one entity 
within internal factors, is reflected in my proposed Concept Mapping (Figure 2.1) as 
having two facets.  The first facet measures, as designated by Ruger (Ruger, 2010) and 
represented in Figure 2.1:  1) self-reported health functioning (e.g., as measured by the 
SF-36, mental functioning and physical functioning (McHorney, Ware John E, Lu, & 
Sherbourne, 1994; Ware, 2009)), and 2) measures of health conditions (e.g., biomedical 
markers, diagnoses, diseases including mental health) and extrinsic risk factors (e.g., 
smoking, exercise, diet, drug use, obesity).  Although these two types of measures 
recognize the existence of both physical and mental health, and are “self-reported”, the 
instruments and measures offered are from the perspective and criteria of the healthcare 
system.  One represents a measure of health functioning (not health status).  The other set 
of measures is based on established medical tests, measurements and guidelines, 
including representing (and limiting) risk factors to a medical model context and its 
expected health-related behaviors.  In contrast, the proposed model addresses a gap in 
understanding of the individual perspective of (their) health status (highlighted in yellow, 
and connected by a blue-hashed line to Health Status), regardless of that as assessed or 
assigned by healthcare system processes and measures.  Not to incorporate such 
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information seems contrary to the Health Capability framework’s primary tenet of 
commitment to individual health, values and goals.  
The second modification is a re-framing of health values as a primary concept, as 
opposed to simply representing and limiting it under internal factors (see Table 2.1).  This 
proposed approach allows for:  1) examining and comparing the interpretation of health 
status based on a biomedical model and criteria versus an individual’s perceived health 
status, and 2) examining a direct relationship between an individual’s health status and 
health values as potential motivators of health action/behavior toward achievement of 
health goals.  
 
Review of Literature 
 
The goal of this literature review is to:  1) provide the background, current status 
and relevant perspectives of the dissertation study’s primary concepts; and, 2) identify 
and discuss the conflicts and gaps in the existing research, literature and perspectives.  
The concepts are presented in the order of historical development and the evolution of 
this dissertation.  These are represented in Figure 2.1 by superscripts in uppercase letters 
adjacent to the corresponding highlighted concepts.  The literature review also provided 
the basis for operationalizing the key concepts into measurable, delineated constructs.  
 
Motivation (and Genomic Testing) (Figure 2.1, Superscript A) 
 
Motivation, an internal factor of Health Capability, has been the subject of several 
DTC genomic testing studies to gain an understanding about the individual’s interest and 
reasons for pursuit of genome testing.  The systematic review of the literature, including 
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qualitative and quantitative studies of DTC users, identified the following themes, 
reasons and desires for individual pursuit of genome testing: curiosity, health-related 
(e.g., disease risk, risk factors), specific disease related (e.g., personal diagnosis; 
condition in the family), health promotion, gaining information about oneself, genealogy, 
helping others, contributing to research, and recreation-related (Goldsmith et al., 2012; 
Gollust et al., 2011; Su, Howard, & Borry, 2011).  
However, the findings of these studies are limited for multiple reasons spanning 
the nature and extent of the sample, the population or data source, the study structure, the 
survey or instrument, and inherent or researcher biases.  Specific reasons include the 
following:  1) study populations involving small and/or convenience samples (Bloss et 
al., 2010; McBride et al., 2009; Su et al., 2011); 2) participants who may not represent the 
stated population (i.e., candidates for genome testing as opposed to actual users, or 
persons who pursued testing because it was free in contrast to self-initiated genome 
testing users who pay for testing) (Kaphingst et al., 2012; D. Kaufman, Murphy, Scott, & 
Hudson, 2008); 3) participants not representative of the general population (e.g., persons 
having an advanced science background or profession, working in the healthcare 
industry, or the majority having a college education) (Bloss et al., 2012; Su et al., 2011); 
4) discrepancies based on the source (Goldsmith et al., 2012) of data (e.g., participant 
answers in conjunction with the labs they used versus postings on outside sites) (Su et al., 
2011); 5) limited percent of survey responders (Bernhardt et al., 2012); 6) survey-
designated answer options for pursuit of testing (Facio et al., 2011); and, 7) potential 
researcher biases, as with interpretation of written motivations (Goldsmith et al., 2012; 
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Su et al., 2011).  For example, a participant’s stated reason for testing is interest in 
knowing one’s genome, and that may be classified as curiosity; however, the underlying 
motivation was concern, hope and curiosity to gain information that might explain 
existing, or undiagnosed symptoms. 
There is a dearth of large-scale genomic testing studies related to motivation (and 
self-efficacy) (Keller et al., 2010), most notably involving actual DTC genomic risk 
testing users who self-initiated testing (Bloss et al., 2010), with limited exceptions.  
However, the Personalized Genomics (PGen) study of 1648 self-initiated DTC genome 
testing users (R. Green & Roberts, 2012b) found that motivation for DTC genome testing 
varied by self-reported health status (R. C. Green et al., 2013) with interest including not 
only risk identification, but also confirmation and etiology of an existing diagnosis 
(Meisel et al., 2013).  Another large-scale study, the Scripps Genomic Health Initiative 
(SGHI), found that 82% of participants would want to know risk findings for non-
preventable conditions (Bloss et al., 2010), although this was not part of the study.  This 
is consistent with results and expectations of another study (Michie, Henderson, Garrett, 
& Corbie-Smith, 2011).  Other studies supported health promotion, adopting a healthier 
lifestyle, and ability to take responsibility for future health as motivators for seeking and 
using genomic information (Cherkas, Harris, Levinson, Spector, & Prainsack, 2010; 
McGowan, Fishman, & Lambrix, 2010).   
 
Summary 
 
Although the findings of DTC genomic testing research has contributed to initial 
understandings related to motivation, studies are few in number with significant 
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limitations.  Specifically these studies:  1) cannot be presumed to represent individuals 
who pursue DTC “on their own”; 2) cannot adequately inform an understanding of health 
values, perception of health and risk, and health needs as motivators for genome testing 
(or future health behaviors); and, 3) are compromised in their ability to inform clinical 
practice, prevention strategies and policy directions (Bloss et al., 2010; Goldsmith et al., 
2012; Goldsmith, Jackson, O'Connor, & Skirton, 2013).  
 
Health Values (Figure 2.1, Superscript B) 
 
The gap in understanding individual interest in, and motivation for, pursuit of 
genomic testing may involve even more basic human factors, such as individual health 
values.  A representative definition of human values involves “… an enduring belief that 
a specific mode of conduct or end-state of existence is personally or socially preferable to 
an opposite or converse mode of conduct or end-state of existence” (Rokeach, 1973).  
This same author purposely avoided use of the terms "ought", "should", and "conceptions 
of the desirable", discussed many types of values, yet health values was not included. 
A systematic review of the literature was performed using PubMed, PsychINFO, 
CINAHL and Cochrane databases.  Since PubMed Medical Subject Headings (MeSH) 
does not include individual health values, a three-step process was used to identify 
relevant records.  First, the term health values were searched as a keyword, identifying 
107, 859 records.  Next, a search using the MeSH terms individual or personal resulted in 
7,939,611 records.  Third, a search stipulating the union of these two sets resulted in 
64,430 records.  In order to identify records specific to genomic information and testing, 
a series of searches was done using these, as well as five other genomic-related MeSH 
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terms.  By combining this result with that for individual health values, 337 records were 
identified (limited to humans).  Six additional records were identified through other 
sources, i.e., a university library resource expert and references cited within a health 
values-related text, for a total of 343 records.  These records were screened by title and/or 
abstract content.  Exclusion criteria included the following:  records lacking mention, or 
the essence, of health values, individual health perspective or personal value of 
genomic/genetic information.  From a complementary perspective, the inclusion criteria 
retained records that used these previously stated terms, or their essence, as well as 
research involving focus groups and qualitative studies of individual health views.  This 
resulted in a final selection of 30 records for full review, including qualitative and 
quantitative studies, perspective articles and commentaries.  Several articles or studies 
did not actually address individual health values or used values from a different context, 
such as equating it with knowledge, and these were excluded.  Corresponding searches of 
PsychINFO, CINAHL and Cochrane databases did not identify any further records.  
Individual Perspective:  Very few studies addressed individual health values as a 
subjective personal concept with qualitative aspects (e.g., what the subjective elements 
are, their relative importance), and their relationship to interest in or pursuit of genetic 
testing.  Studies of relevance typically used a survey or targeted focus groups for specific 
disorders or conditions, identifying value or belief themes that influenced interest in 
genetic testing or information (Doukas, Fetters, Coyne, & McCullough, 2000; McBride et 
al., 2009; Pivetti, Montali, & Simonetti, 2012).  Although these studies spanned very 
different populations, from men of various ethnicities aged 18-90 related to prostate 
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cancer risk and gene testing, to 20 pregnant women and new mothers related to uptake of 
prenatal genetic testing (PGT), the identified themes and reasoning were similar in 
nature.  The essence of themes were the following:  1) usefulness and benefits of 
information (e.g., for making choices, preparing, family planning, taking action such as 
changing diet or exercise; 2) interest in and concerns about susceptibility, risks and 
consequences; 3) beliefs about barriers; and, 4) issues of morality and trust (Doukas et 
al., 2000; McBride et al., 2009; Pivetti et al., 2012).  These studies were few in number, 
limited to specific conditions, have small sample sizes and/or only partially address the 
issue of individual health values; however, they also attested to this concept’s influence 
and the need for further research.  
Cultural and Societal Influences:  The cultural and societal influence on values 
and perceptions was also evident.  What is perceived as important to an individual or 
community group may be of little value by healthcare system standards, and vice-versa 
(e.g., knowledge of risk prior to symptoms versus reduction in mortality).  This 
perpetuates a frustrating, costly, resource draining and ineffective cycle for practitioners, 
patients, educators and policy makers.  Studies, such as those involving Fragile X genetic 
screening of children in the Colorado schools’ special education classes, found that 
interest in genetic testing reflects cultural beliefs regarding the importance of genetic 
information and expectations about future possibilities (Nelkin, 1996).  The author also 
posits that the media fosters a public impression of social meaning to genetic testing that 
it may support individual needs.  Whether or not one agrees with this position, there is no 
question about the existence of marketing related to the value and potential of 
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genetic/genomic information and testing, an increasing public awareness and interest, and 
the healthcare view of its limited clinical utility (Ducournau, Gourraud, Rial-Sebbag, 
Bulle, & Cambon-Thomsen, 2011; Jordens, Kerridge, & Samuel, 2009). 
Healthcare System Perspective & Issues:  The literature review identified one 
relevant large scale study involving 12 focus groups and 97 healthcare providers (i.e., 
genetic counselors, physicians and nurses in four different geographic areas) that 
demonstrated discrepancies and conflicts encompassing sixteen major ethical and 
professional domains (Veach, Bartels, & LeRoy, 2001).  Value-associated conflicts were 
among the second and third most common issues, spanning intrapersonal (professional 
with self), interpersonal (between professional and the patient, or a colleague), and extra-
personal (among patient family members) relationships.  It is noteworthy that all 
examples of values’ conflicts (5) provided by the study authors had a moral basis.  Yet 
the common occurrence of conflicts in the broader spectrum of health-related values, 
especially between healthcare providers and patients as well as healthcare providers with 
each other, supported the relevance and need for studies to examine individual health 
values.  Such information relates to the provision of meaningful healthcare services, 
prioritization and allocation of healthcare resources, expectations for patient health 
behaviors and outcomes, support for individual healthcare values, and the development of 
effective policy (Ruger, 2010; J. P. Sturmberg et al., 2012). 
Health Values as an Economic Measure:  An economic perspective of health 
value was a common component among the identified studies.  In healthcare, value is 
often defined as an outcome/cost ratio, such as cost-effectiveness (CE) or incremental 
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cost-effectiveness ratio (ICER) (Kwon et al., 2010; Woolf, Lewin, Marks, Fielding, & 
Sanchez, 2009).  CE may be based upon the achievement of significant differences in 
outcomes, such as morbidity, mortality or health benefits, often within a given time 
frame, related to a specific treatment, strategy or technology (Tilburt et al., 2011).  An 
economic view of health value also exists in the prevention context.  Two examples are 
the assignment of a CE threshold of $50,000/year of life gained in the context of breast 
cancer treatment and testing (Kwon et al., 2010), and individual willingness to pay for 
services (i.e., genetic counseling, information and testing services) based on the 
contingent valuation method (Eden et al., 2013).  Individual values and quality of life 
(QOL) factors are typically not included (Tilburt et al., 2011).  A quasi-economic view of 
health values, captured by the idea of worth or tangible value of genetic/genomic 
information from the framework of exchange, gift and genetic responsibility theories, 
was demonstrated in a study of 752 donors of specimens for genetic research (Michie et 
al., 2011).  This study’s results, despite the focus on altruistic motivation while respecting 
a monetary value of donations, distinctly supported the existence of underlying individual 
health motivations and expected personal health value for participants.  Of donors, 70.8% 
wanted to find out information about their own health, although informed consent 
specified that was not an intended use for the specimens.  Donors also spoke of their 
specimens in the context of diagnosis rather than research use, with an expectation of 
results, consistent with a personal value to their genetic information.  
Summary & Discussion:  The studies reinforced the existence and influence of 
underlying individual health values, the expectation and/or desire for personal 
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information, the potential (or perceived) value of genomic information to the individual, 
and the necessity for further research to gain a better understanding of future applications 
in healthcare.  Existing gaps include the individual (patient, researcher, system) 
subjectivity in defining and operationalizing health values, its relationship with other 
personal health components (e.g., perceived health status), and its contribution to an 
individual’s motivations, decisions, actions and expectations for healthcare information 
and rights of self-determination, including the pursuit and use of genomic testing 
(Nyrhinen, Hietala, Puukka, & Leino-Kilpi, 2009).  There was also a distinct gap in 
understanding and perspective involving individual health values related to clinical utility 
versus personal utility (Bollinger, Scott, Dvoskin, & Kaufman, 2012; Bunnik et al., 2011; 
Grosse et al., 2009).  A practical question arises about the use of alternate definitions and 
measurements for health value, specifically focusing on individual subjective health 
values, that may better delineate personally relevant influences, how they interrelate with 
other subjective personal health components (e.g., perceived health status), individual 
needs and health goals, as well as the value and personal utility of genomic information 
as it relates to individual health choices and behaviors. 
 
Perceived Health Status (Figure 2.1, Superscript C) 
 
A systematic review of the literature was performed concerning the individual’s 
perceived health status and this is addressed in Chapter IV.  The review also includes 
review of literature and discussion about the two main methods used to capture this 
construct, specifically a single question or a measurement instrument.  The focus in this 
section is restricted to relevant foundational and contextual information.  
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The healthcare system traditionally has viewed health status using the biomedical 
model, focusing on the presence or absence of symptoms, illness or increased risk as 
defined by the presence of objective scientific evidence to make a diagnosis, justify 
intervention and determine treatment (Borrett, 2013).  Many situations do not meet these 
standards.  The need for examining health and health status from the subjective individual 
perspective is recognized, yet the healthcare system is struggling with how to do this, 
what models to use, what values to include and the mechanisms to use for evaluation 
(Loughlin et al., 2013).  
Studies that include an individual’s perspective of health status typically involve 
the use of a survey or questionnaire that limits capturing this construct to a single 
qualitative, yet quantitatively measured, item or focus for analysis.  For example, one 
study of DTC users of genomic testing asked participants to rate their (overall) health 
using a 5-point Likert-type scale ranging from very poor to very good (Bloss et al., 2010), 
while a study of African-American males focused on cardiovascular disease examining 
health status, but from the context of health abilities (and functioning) using a health 
practices scale (DeCuir, 2007).  Health status and health values were frequently framed in 
the context of health risks, risk likelihoods and binary situations (Wang et al., 2009).  
These risk and binary approaches lack appreciation of the broader and qualitative 
dimensions of health values and individual freedoms, and foster an all-or-nothing stance 
that minimizes the potential contribution of research in multifactorial and complex 
common disorders, which includes predictive genomic testing (Boenink & van der Burg, 
2010). 
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Although the search focus was health status, the majority of records identified and 
reviewed were disease or risk focused, involving quantitative or mixed methods studies 
that included measures of perceived health status based on the study focus or need.  The 
most frequently used instrument (8/19; 42%) for evaluating perceived health status was 
the SF-36 (Foottit & Anderson, 2012; Funk et al., 1997; Gartsman, Brinker, Khan, & 
Karahan, 1998; Hunter, McKee, Black, & Sanderson, 1995; Lindsay, Smith, Hanlon, & 
Wheatley, 2001; Mattera et al., 2000; McHorney et al., 1994; Ware, 1976, 2009).  This 
instrument has been suggested for measuring health status and health functioning in the 
Health Capability conceptual framework (Ruger, 2010).  The SF-36 encompasses 36 
questions, spanning eight scales (physical functioning; role-physical; bodily pain; general 
health; vitality; social functioning; role-emotional; and mental health), plus the perceived 
general health status item.  The repeated use of this measure across more than 4,000 
studies has supported its validity and reliability (Ware, 2009).  This is addressed, together 
with other instruments in common use, in Chapter IV.  
These instruments have limitations related to the following:  1) the limited 
number of questions, reflecting the inability to cover all desired health status related 
content areas; and, 2) the survey structure in that questions provide all answer choices, 
without open ended questions, thereby precluding the ability to capture unique individual 
subjective concerns or issues.  These issues may alter the understanding of an 
individual’s perceived health status, and their contribution to influencing health related 
needs and actions, such as the decision to pursue genomic testing.  Based on this search, 
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no instrument was identified that encompassed an individual’s perception of health status, 
and subjective personal health values, concerns and goals.  
 
Discussion 
 
The need for further research to examine and foster understanding about the 
individual’s reasons for independent pursuit of genome testing was demonstrated by the 
results of a literature review (Goldsmith et al., 2012) attesting to gaps, biases, lack of 
actual users and likely underrepresentation of persons pursuing DTC genome testing.  
These findings also lend support to the current study’s proposal that an individual’s 
perception of health is a complex construct composed of many components, differentially 
relating on an individual level to motivation, health values and goals, and health 
behaviors.  The elements identified, yet not combined or examined for potential 
interactions in a research study thus leaving unanswered questions, include the following:  
physical and/or psychological, i.e., disorders or symptoms (Heshka, Palleschi, Howley, 
Wilson, & Wells, 2008); perceived and actual health risks, such as for multifactorial 
conditions (Zeggini et al., 2008); familial conditions and genetic aspects (Heshka et al., 
2008; O'Neill et al., 2009); environmental influences, as with Parkinson’s disease (Do et 
al., 2011); lifestyle choices, such as smoking (Janssens et al., 2011; Saudny, Cao, & 
Egeland, 2012); and, individual goals, such as health promotion (Juengst et al., 2012; 
Lea, Skirton, Read, & Williams, 2011).  Awareness of these components and possible 
interactions challenge previous research findings based on simplifying and restricting 
health status to representation as a biomedical, or single entity.   
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These health-related components are noted in the Concept Mapping, Figure 2.1, 
as comprising Individual Perceived Health Status.  This study incorporates only the 
perceived risk component (see following).  The other components will be examined in 
future research. 
 
Risk Perception (Figure 2.1, Superscript D) 
 
Perception of health risk is a factor associated with individual pursuit of genomic 
testing (Gollust et al., 2011).  Most studies use the terms perception of risk, risk 
perception and perception of health risk synonymously without defining these terms, but 
instead imply their meanings based on the study context, population focus and/or 
operationalization of items measured (Hahn et al., 2010; D. J. Kaufman et al., 2012; 
Lerman, Rimer, & Engstrom, 1991; Lipkus, 2007; McAllister, 2003; van Maarle, 
Stouthard, & Bonsel, 2003; Watson et al., 1999).  For example, perception of risk was 
used as disorder specific for breast cancer (Watson et al., 1999) and for Alzheimer’s 
disease (among others) (Heshka et al., 2008).  The single focus of risk perception in these 
studies can be viewed as a strength for statistical analysis, yet it is also a limitation if 
perception of risk includes qualitative components not sought, measured or recognized as 
important to individual health values and goals.   
Philosophical Origins and Measures of Risk:  Two fundamental views of risk 
operate in parallel based on cognitive psychology and neuroscience.  There is the 
“analytic system” that uses algorithms and norms, and the “experiential system” based on 
individual experiences, affect (emotions) and values (Slovic, Finucane, Peters, & 
MacGregor, 2004).  The former, consistent with a biomedical scientific model, reflects 
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objective, reasoned and logical processes that can be measured, quantified and controlled.  
The latter reflects individual health values, subjectivity, human dynamics and personal 
goals, consistent with valuing genomic information and mapping back to the Health 
Capability concepts and principles.  
Risk perception incorporates “a situation or an event where something of human 
value (including humans themselves) is at stake and where the outcome is uncertain” 
(Rosa, 1998), a risk target (self vs. others) (Sjoberg, 2000), and “how concerned we are 
about the consequences” (Sjöberg, Moen, & Rundmo, 2004).  Three key features 
emerged, all subjective in nature, being: assessment of probability, an undesired 
event/entity, and concern about the impact of the outcome for self.  Individual perception 
and interpretation of health risk is paramount.  This is not confined to a single, static, 
isolated risk factor.   
Defining Individual Perception of (Perceived) Health Risk:  For the purpose of the 
current study, individual risk perception is defined as:  Individual recognition or 
appreciation of real or believed vulnerability, compromised health status and/or 
likelihood of a disease(s), disorder(s) or condition(s) (specific or in general), as either 
increased relative to others, or existing to an extent beyond that acceptable to that 
individual (BusinessDictionary.com, 2012; Dearborn & McCullough, 2009; Gregory & 
Mendelsohn, 1993; Griffith, 2011; Lloyd et al., 1996; McAllister, 2003; "Risk 
Communications Bibliography," 2012; Rosa, 1998; Slovic, 1987; Walker, Mertz, Kalten, 
& Flynn, 2003; Watson et al., 1999).  This definition facilitates the operationalization of 
various potential individual influences contributing to an individual’s perception of risk 
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(which parallel components relevant to an individual’s perception of health, as noted 
previously).  
Genetics/Genomic Context:  Perception of risk, from a genetic perspective, has 
been operationally defined and measured in different ways (Lipkus, 2007).  These 
included the following:  quantification of risk for a specific disease, e.g., cancer, using 
numeric measures (comparative; binary; personal; population percentage of risk) (Kelly 
et al., 2007); measuring risk likelihood for selected diseases, e.g., as with a Likert-type 
scale (Lerman et al., 1991); assessing the extent or category of risk (e.g., present/absent; 
high/moderate/low); and, accuracy of individual recall for disease specific numeric risk, 
test result or biochemical screening values (Kaphingst et al., 2012; D. J. Kaufman et al., 
2012; van Maarle et al., 2003).  
Risk perception research in genetics has examined this phenomenon in 
participants, primarily after receiving the results of genetic testing (Heshka et al., 2008; 
D. J. Kaufman et al., 2012).   A review of the literature on the perceived risk, 
psychological and behavioral impacts of genetic testing identified 35 articles and 30 
studies (Heshka et al., 2008).  No differences were found in risk perception between gene 
mutation carriers and non-carriers 12 months post-test, postulating one explanation for 
the lack of differences as possible differences in risk perception between these two 
groups.  A gap in research exists related to the examination and understanding of 
perceived health and risk before genome testing, its potential influence on individual 
health values, expected results and pursuit of testing, and the impact on health-related 
behavior.  Although this has been studied to a limited extent, the focus on risk perception 
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has been disease/condition specific or based on case scenarios, as opposed to actual 
personal results and experience (D. J. Kaufman et al., 2012).  
 
Concepts Assumed in the Current Study (Figure 2.1, Superscripts E and F) 
 
Self-efficacy (Superscript E):  This concept, among Health Capability’s internal 
factors (see Table 2.1), includes coping behavior, the extent of energy expenditure, and 
sustaining in the face of obstacles and aversive experiences, are supported by behavioral 
change theory (Bandura, 1977).  Self-efficacy is defined as “…the judgments people hold 
about their capacity to master specific tasks and to cope with challenging situations (Oles 
et al., 2013) (p.48).  Self-efficacy has relevance to the well-established health-related and 
prevention theories including health belief, health locus of control and health capability 
(Janz & Bcker, 1984; Norman, 1995; Rosenstock, 1974; Ruger, 2010).  Studies involving 
self-initiated testing and genetic risk concerns support the concept of self-efficacy as 
relevant to the pursuit and/or use of genomic testing (Grispen, Ronda, Dinant, de Vries, 
& van der Weijden, 2011; McGowan et al., 2010).  Thus, persons whose health goal was 
to secure genome testing, and who independently accomplished this testing despite 
traditional healthcare system barriers, all exhibited self-confidence and self-efficacy.  
Health Knowledge (Superscript F):  Defining and measuring the concept of health 
knowledge, an internal factor of Health Capability, was included in several genetics 
studies (Haga et al., 2013; Leighton, Valverde, & Bernhardt, 2012).  This poses a myriad 
of challenges, not the least of which is determining the relevant focus.  The gap in 
research addressed by this study relates to individual perceived health status, health 
values, reasons for pursuit of genome testing and perception of health risk.  These 
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subjective concepts do not require, or necessarily correlate with, genetics knowledge.  
Genetics knowledge will not be examined in the current study.  As further justification 
for this decision, previous studies of DTC genome testing users has consistently shown 
participants to tend to have higher levels of education than the general population, to tend 
to understand that genome testing results relate to potential risks not outright diagnoses, 
and that discussion with healthcare providers is recommended before taking any health-
related action.  These studies also demonstrate inherent biases, such as the nature of the 
questions posed, interpretation of answers and scoring, use of accuracy as a surrogate for 
knowledge, the nature of knowledgeable comparison groups, and assumed gain in 
knowledge if research educational materials are accessed (Keller et al., 2010; Leighton et 
al., 2012; van Maarle et al., 2003).  
 
Summary and Relationship to Other Chapters 
 
This chapter described the genomics and healthcare environment, the increasing 
use and evolving potential of genome testing, and the issues and challenges related to 
individual pursuit of this testing.  Research questions and hypotheses address the 
components potentially influencing individual self-initiated pursuit of DTC genome 
testing, from the perspective of an individual’s subjective perception of their health 
versus health status based on healthcare system parameters.  Other possible subjective 
influences include motivating elements, individual health values and goals, and perceived 
risk.  The concept mapping proposed in this chapter operationalizes the conceptual 
framework, Health Capability.  Relevant concepts and components of the Health 
Capability model related to the study are presented, along with corresponding literature 
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reviews.  These concepts include motivation, health values, perceived risk and perceived 
health status.  Perceived health status is the main concept based on literature reviews.  
The concept map is examined along with approaches and instruments to measure this 
concept.  This background and processes lead to the study presented in Chapter V.  The 
DTC genomic testing research supports the importance of concepts essential to this 
dissertation research study and to Health Capability.  However, if and how these concepts 
and components interrelate, influence health-related priorities and decisions, impact 
health action and behavior, and compare with traditional perspectives of health status 
have not been examined.  Data from the PGen study of DTC genome testing users (R. 
Green & Roberts, 2012b), forms the basis for this study.  It offers an opportunity to 
address these questions in self-initiated users with no input from healthcare providers or 
researcher-based influences prior to their decision to pursue genome testing.  The broader 
implications of this research are addressed in Chapter VI. 
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CHAPTER III 
 
PERSONALIZED GENOME RISK TESTING:  EXAMINING A MODEL TO INFORM 
AND AMELIORATE THE DICHOTOMY FACING HEALTHCARE 
 
 
Introduction & Background 
 
This chapter is an article submitted for review and publication to the Journal of 
Health Services Research & Policy.  The following pages are copied from the PDF file, 
exactly as submitted in compliance with journal requirements.   
The content of this article complements and extends information on the Health 
Capability conceptual framework.  This model encompasses the concepts and 
prioritization of individual health values and goals, from both a philosophical and a 
practical basis.  These are integral to this study.  The concepts/constructs of perceived 
health status, health values (and goals), health functioning and health agency relate 
directly to the users of Direct-to-Consumer (DTC) genomic testing.  In the Health 
Capability profile, internal and external health-related factors are recognized as 
influences on the individual at different system levels (individual, family/community, 
healthcare systems, and societal/governmental).  However, a concept map of these 
relationships does not exist.  This article includes a proposed structure and relationship of 
essential concepts that became the Concept Mapping presented in Chapter II.  This 
included an expansion of some components for enhanced health-related applications, 
such as the context of genomic testing in healthy persons.  Components of this map were 
tested in the study (Chapter V).  
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Figure 3.1:  Conceptual model of health capability. 
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Figure 3.2:  Conceptual process model of health capability. 
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CHAPTER IV 
PERCEIVED HEALTH STATUS AS A MEASURE FOR ASSESSMENT   
AND MANAGEMENT OF HEALTHY PERSONS:   
A REVIEW OF THE LITERATURE  
 
 
Introduction & Background 
 
This chapter is an article submitted for review and publication to the journal 
Research and Theory in Nursing Practice.  The following pages are copied from the PDF 
file, exactly as submitted in compliance with journal requirements and author guidelines.  
This article is a systematic review of the literature pertaining to the concept of 
perceived health status.  It also includes a focused and detailed presentation of 
approaches and instruments to measure this concept.  Knowledge of this concept, 
approaches used to determine its influence, and measurement instruments are essential to 
this dissertation and the Health Capability paradigm.  This knowledge is relevant to 
operationalizing perceived health status, as well as to the data analysis and interpretation 
of the study results (Chapter V).  The research results will contribute to understanding the 
dimensions and influence of perceived health status, its role in the Health Capability 
(Chapter III), and its relevance to clinical practice and research.  The dissertation study 
results related to self-perceived health status (as well as health values, Chapter II) will 
also contribute to the further development of a functional/operationalized model for 
Health Capability, to assessing appropriate methods and instruments for measuring these 
concepts, and possibly to broader applications across traditional and evolving healthcare 
(Chapter VI).  
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Figure 4.1:  Conceptual Model of Health Capability. 
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Abstract 
 
Purpose:  To:  1) examine health status, categorized by both individual perceived 
health and biomedical health (medical diagnosis), for discrepancies and to characterize 
group differences, and 2) assess individual perceived health status and health values as 
influencing self-initiated genome testing.  Methods:  1464 direct-to-consumer (DTC) 
genome testing users, participants in the Impact of Personal Genomics (PGen) study, 
were classified into four mutually exclusive health status groups.  Groups were analyzed 
on reasons for pursuit of testing, individual risk perception and health values by Chi-
square (
2
), t-tests, ANOVA and correlations.  Results:  All four categories were 
represented, confirming discrepancies between individual and biomedical health status.  
One group may represent the “worried well”.  Interest in health-related information was 
high (98–99%) across all groups.  Two items distinguished all groups (interest in 
pharmacogenomics information and learning risk for other diseases (p < .001), while 
some items distinguished one group.  When groups differed, perceived rather than 
biomedical health status was often involved, yet both factors demonstrated influences 
(variable dependent).  Risk perception was moderately correlated (.301) with health 
status group.  Conclusions:  Individual perceived health status and health values are 
significant factors influencing self-initiated health action (pursuit of genomic testing), 
suggesting benefit of integration and complementarity in effective healthcare practice, 
research, models and policy.  
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Keywords: [5] 
 
Perceived health status, individual health values, personalized healthcare, risk 
perception, genomic testing 
 
Introduction 
 
Through 2014, an estimated one million persons have pursued direct-to-consumer 
(DTC) genome testing, providing them with health-related results
1,2
.  Despite recent FDA 
regulatory action currently restricting DTC labs from marketing and providing health-
related genomic testing
3,4
, final authoritative determinations are yet to be made
5
.  
Nonetheless, official positions are unlikely to thwart public interest, demands and 
expectations regarding genomics in healthcare
6-8
.  Motivations for individual pursuit of 
genome testing identified through research span curiosity, desire for information about 
health (risks), support for research, genealogy, and fun/entertainment
9-13
.  These results 
are limited, however, by factors including recruited or convenience populations, small 
sample size, anticipated versus actual genome testing, example cases versus actual 
results, equating genetics knowledge with ability to understand or use genomic 
information appropriately, use of surrogate measures for subjective concepts (e.g., 
absence of medical diagnosis as individual good health) and the nature of survey 
questions
9,13-17
.  This latter issue regarding questions potentially compromises findings 
and interpretations in ways not previously appreciated or readily apparent, e.g., what 
questions are posed (albeit objective); use of technical or culturally-influenced 
terminology; limited, duplicitous or confusing answer choices; and researcher/clinician 
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over-simplification or misunderstanding of participant text responses.  Thus perpetuating 
that “we do not know what we do not know”18.  
Important unanswered questions and gaps in knowledge remain.  Do individuals 
who pursue DTC genome testing deem this information essential to their health and 
health management decisions?  Do they represent the “worried well”19, or proactive 
prevention-oriented persons, neither deemed needy of over-burdened healthcare services?  
And perhaps, of most relevance, “Does individual perceived health status (regardless of 
biomedical health status) and personal health values act as drivers influencing individual 
pursuit of genome testing or value (personal utility
20
) of genomic information?  Answers 
to these questions extend well beyond the genomics context.  
Perceived health status, although recognized as a powerful predictive factor in 
studies of mortality and morbidity
21-24
, has seen limited exploration in the context of 
prevention and health promotion research.  In spite of its potential importance, it is 
essentially treated as an ancillary or complementary item/measure
17,24
 rather than as an 
integral, and possibly even determinative, factor in individual health priorities and 
decisions.  Perceived health status, by its subjective nature, must encompass some 
internal personal measure(s) for interpretation of one’s health (and/or risks)25 resulting in 
perceived gradations of acceptable, unacceptable or choice to ignore.  Depending upon 
that assessment, an individual may determine whether needs exist and if so, whether or 
not to take action.  This process also implies the existence of personal health values 
(distinct from those of healthcare, e.g., cost/benefit)
26
 and goals that influence 
motivations to action.  Thus, individual health-related actions can be viewed as part of an 
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interactive process with perceived health status and personal health values and goals, 
consistent with the conceptual basis (Health Capability
27
) of the current study.  
The population studied here represents a rare, naturally occurring sample of both 
medically diagnosed as well as healthy persons (not as controls), unaffected by the 
influence of clinicians, researchers or a controlled study prior to independently deciding 
to pursue genome testing, who subsequently enroll in the PGen study
28
.  This study 
sought to explore the influence of subjective individual factors, combined with and 
distinguished from traditional healthcare contexts, specifically perceived health status, 
health values, risk perception
17,29-32
 and reasons for pursuit of genome testing.  This 
knowledge relates not only to DTC users, but potentially contributes to identifying 
previously unrecognized individual motivations and values that impact many health 
behaviors, as well as fostering individual-practitioner partnership and respect in 
healthcare priorities and decisions, and more effective use of healthcare resources.  
 
Materials and Methods 
 
Study Design  
 
This study examined survey data from persons who independently pursued direct-
to-consumer (DTC) genome testing and voluntarily participated in the National Institutes 
of Health funded Impact of Personal Genomics (PGen) Study 
33
.  The PGen initiative 
developed three surveys using items (e.g., multiple-choice, Likert-type) from existing 
genetics research instruments with previously demonstrated reliability and validity 
14-16,34-39
.  
Items spanned domains and content relevant to the current study and its conceptual 
framework (Health Capability)
27
, including but not limited to motivations and 
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expectations (for genome testing), risk perception, socio-demographics, personal utility, 
individual health values, individual medical history, family history and health-related 
behaviors.  Surveys were completed in 2012, two weeks prior to pursuit of genome 
testing (BL), and two weeks (2W) and six months (6M) after testing.  This study, 
approved by the PGen Review Board, Harvard Medical School, and the Clemson 
University IRB, utilized de-identified study-specific data provided in an SPSS format, 
primarily from the BL survey with relevant items solely in the 2W survey.  
 
Participants & Survey Dissemination 
 
Potential participants were invited via the health-based social networking site 
PatientsLikeMe and a banner on the Pathway Genomics website.  Personal genome 
testing (SNP analysis), including provision of health-related results, was pursued through 
either the 23andMe or Pathway Genomics laboratory
40,41
.  The original PGen population 
consisted of 1,838 consenting persons, with 1,648 eligible after eliminating partial or late 
received surveys; 1,464 persons completed the second survey and were eligible for this 
study.  They were categorized into four mutually exclusive health status groups (the 
independent variable) based on dichotomizing perceived health and medical diagnosis 
status.  Participants included males and females, ages 19-94, of different races, ethnicities 
and educational, socioeconomic and occupational backgrounds.  
 
Data Analysis 
 
Statistical power was assessed based on the number of eligible PGen participants, 
as well as the numbers anticipated for the current study’s groups.  This was determined to 
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be sufficient for the intended data analyses, with a power of .8 and at a 0.05 level of 
significance 
42
.  It is relevant to note that the study variables are qualitative and subjective 
in nature, were assessed primarily by Likert-type scale items (with 3-5 choices), and were 
suspected to be in an interrelated, interdependent relationship (consistent with this study’s 
conceptual framework).  Descriptive statistics (mean; standard deviation) and frequency 
analyses were done to characterize health status groups (see Table 5.1).  Groups were 
compared on socio-demographic items, reasons for pursuit of genome testing, risk 
perception and individual health values using Chi-square (
2
), t-tests and/or analysis of 
variance (ANOVA) (depending on whether these dependent variables were categorical or 
continuous).  Statistically significant differences identified by ANOVA were subjected to 
independent t-tests between two-group combinations to identify the source/s of 
significant difference.  Original PGen scoring of variables was maintained, or if 
modified, variable direction and construct integrity was preserved.  Operationalization of 
measures is addressed in the Results sections.  Limited qualitative data was examined by 
query of study-relevant text answers for targeted terms (keywords) to identify and 
quantify existence of factors that could impact health status groups and/or interpretation 
of results (e.g., mention of undiagnosed health problem, or diagnosis not included in the 
survey).  
 
Results 
 
Health Status Groups 
 
Respondents were classified into four mutually exclusive health status groups by 
dichotomizing perceived health status and health status based on medical diagnosis.   
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Table 5.1.  Characteristics of PGen study participants
1
 included in health status 
groups. 
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Diagnosis related to presence or absence of any of fourteen survey-specified types of 
conditions:  arthritis, asthma, cancer, chronic kidney disease, diabetes, eye, 
gastrointestinal, heart, high cholesterol, lupus, mental illness, neurological, obesity and 
psoriasis.  Perceived health status was dichotomized as: good (good, very good, 
excellent) or not good (fair, poor).  Of 1,464 eligible surveys, two lacking answers for 
perceived health status were eliminated, as were another seven noted among the 
following health status groups, leaving 1,455 persons:   
 
 Diagnosed Ill (DI):  213; one or more diagnoses (mean 4.40; range 1-10) and 
perceived health as not good. 
  
 Medically Managed (MM):  950; one or more diagnoses (mean 2.75; range 1-
9) and perceived health as good. 
 
 Healthy (H):  292; without a diagnosis and perceived health as good. 
 
 Health in Question (HQ):  7; without a diagnosis and perceived health as not 
good (eliminated due to small size; see Discussion). 
 
Diagnoses types between the DI and MM groups were not statistically different 
except for arthritis, eye, gastrointestinal, obesity and neurological conditions (p < 0.05), 
and kidney disease (p = 0.05).  Socio-demographic characteristics, noting significant 
differences on several variables, are summarized in Table 5.1.  T-tests clarified most 
differences involved the Healthy group.  The DI and MM groups had similar mean ages 
(51.2 and 50.1, respectively, compared to 37.5 for the Healthy) and percent having 
biologic children (54.5 and 55.7%, respectively, compared to 37% for the H).  Sex was 
only significantly different (p = 0.006) between DI and H groups (69.5% versus 55.5% 
female, respectively).  Participants were primarily White, 5-6% Hispanic, and minorities 
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represented fewer than 5% (African-Americans, Hawaiian/Pacific Islanders, Asians, 
American Indians).  Income was significantly different (p < 0.001) by t-test comparisons 
involving the DI group.  Individual decision-making role with healthcare providers 
demonstrated the majority, regardless of group, shared in responsibility; however, the DI 
and H groups were significantly different (p = 0.034). 
 
Reasons for Pursuit of Genome Testing 
 
Importance of twelve specifically queried reasons for pursuit of genome testing is 
summarized in Table 5.2, including five identified as significantly different.  All other 
items, except one, were uniformly rated as important.  Finding out about personal 
response to different medications distinguished all three groups (p < 0.001 for both DI 
group comparisons; p = 0.037 for MM with H).  T-tests identified the DI group as the 
source of most between group significant differences (p < 0.01 for personal risk for 
disease, creating a better plan for the future, and test seeming fun/entertaining).  The 
Healthy group was the source of significant difference for only importance of health 
condition risk information for children (p < 0.01, with either DI or MM).   
A text response to reasons for pursuit of genome testing was queried for keywords 
including “undiag…”, “health problem”, “I have”, “unknown” and “health concern” to 
identify frequencies of participants expressing desire/hope to get information about 
undiagnosed health problems or diagnoses beyond those in the survey.  Of 1,352 
respondents, twenty-eight instances were identified (see Table 5.2).  This information 
would have changed health status group assignment for two cases (from H to MM).  
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Risk Perception 
 
Risk perception analysis encompassed two approaches.  Frequencies 
(percentages) of perceived increased risk to develop each of twelve survey-specified 
conditions is presented in Figure 5.1.  Another twelve conditions are not included due to 
poor response rate (< 40%).  Figure 5.1 illustrates vertically, by increasing depth of color 
of health status group columns, an apparent trend in perceived risk being lowest in the 
Healthy, in the mid-ranges in the Medically Managed, and highest in the Diagnosed Ill.  
In contrast, cluster patterns across health status groups are represented horizontally in 
Figure 5.1 (bracketed, left side), e.g., three conditions at the bottom and four at the top 
demonstrating parallels in highest perceived risks across all three groups. 
Second, risk perception was captured as a single variable representing the total 
number of survey-specified conditions (0-24) that each individual noted as being at 
perceived higher than average chance to develop (survey language).  This type of additive 
approach has been used previously in research
43
.  Group means were significantly 
different (p < 0.001).  The means (and range of conditions) were: Healthy 1.61 (0-8), 
Medically Managed 3.01 (0-17) and Diagnosed Ill 4.36 (0-13).  Between group 
comparisons by condition, presented in Table 5.3, demonstrate the Healthy group as 
significantly different from the DI for all nine conditions and from the MM on seven 
conditions.  Comparison between the two groups with medical diagnoses (DI and MM) 
demonstrated significant differences relating to colorectal and lung cancer, diabetes and 
heart disease, despite similar mean ages.  Among persons indicating no increased risk for 
any of the 24 conditions, 92.4% indicated their perceived health status as good.  In 
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Figure 5.1:  Percentage of Individuals within Health Status Groups at Perceived 
Above-Average Chance to Develop Survey-Specified Conditions. 
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contrast, 62.5% of persons having no perceived increased risk had one or more medical 
diagnoses.  
To potentially identify if risk perception was differentially associated with 
perceived health status, with health status based on existing medical diagnosis, or with 
the combined health status, Pearson correlations were done.  Perceived risk was weakly 
correlated with medical diagnosis status (.272), was moderately correlated with health 
status group (.301) and was moderately correlated (.326) with perceived health status.  
This suggests a greater influence by perceived health status.  All correlations were 
statistically significant at the p = .01 level (two-tailed).  
 
Health Values 
 
Consistent with existing literature, individual health values were operationalized in this 
study by items (ten pre-testing and six post-testing) encompassing participant indicated 
importance, interest, consideration or value (in the context of genomic testing or 
information)
27,44
.  Table 5.4 summarizes the results of answers pre-testing, including 
details of the four achieving statistical significance.  The DI group was significantly 
different from both the MM and H groups on all four items.  The MM and H groups were 
similar on two of the four, as well as being within 1.5% of each other on three other 
items.  The Healthy group was significantly different from both the DI and MM groups 
on one item.  All three health status groups were significantly different regarding interest 
in learning information about personal response to drugs and indicating interest in 
learning risk for other disease/s.  Two items not achieving statistically significant  
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differences (see Table 5.4) had uniformly high levels of interest (89.5-99%).  The value 
of obtaining information about traits could not be assessed reliably because of missing 
data (30.8% - 59.2%). 
Six post-testing items inquired about genome results in relation to individual 
health value.  Results on Likert-type items (five scored 1-5, lowest for not at all or 
strongly disagree; highest for extremely or strongly agree) identified value for all items 
across all health status groups, and a pattern of highest to lowest scores from DI, to MM, 
to H.  Overall, means ranged from 3.46 (between neutral and somewhat agree) in the 
Healthy group (for results helping to decrease risk of getting sick), to 4.16 in the DI 
group for results being valuable.  This latter item had uniformly high agreement across all 
three groups (means 4.07 and 3.98 for MM and H, respectively).  Statistically significant 
differences were identified by t-tests on two items:  1) importance of information as 
influencing future health management, between the DI and H groups (p = 0.019) and, 2) 
ability to use the information to improve health (p < 0.001) between all groups.  
 
Discussion 
 
This large-scale study of self-initiated DTC genome testing users demonstrated 
that categorizing individuals by health status based on both perceived health and 
existence of a medical diagnosis created the four hypothesized groups, each having 
clinically meaningful differences.  This supported not only the previously established 
influence of perceived health status related to existing medical conditions and 
morbidity
21,22
, but contributed new awareness of its involvement in the health-related 
choices of healthy persons. 
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Health Status Groups 
 
The groups were characterized to identify distinguishing characteristics and 
answer the research questions.  The Healthy group represents individuals who generally 
do not come to the attention of the healthcare system, and the discrepant health status 
groups were also of interest. 
An unexpected finding was that there were only seven persons in the Health in 
Question group.  This group, who had no diagnosis but indicated their health as not good, 
could represent the “worried well”19, persons lacking diagnosis for an existing health 
problem, and/or be hoping for some type of specific information.  The low number could 
be explained if larger numbers exist but are subsumed into other groups, e.g., into the 
MM or DI because they have a co-existing survey-specified diagnosis.  This 
consideration is supported by the 28 persons with diagnostic concerns identified through 
analysis of text answers to reasons for pursuit of genome testing; however, none were in 
the HQ group.  Mitigating factors include limited query, attribution of concerns to others 
(e.g., relatives, thus were not counted), not articulating this concern in their text answer, 
or non-response.  It could also be that an existing medical diagnosis was their highest 
priority and/or that other concerns are addressed during regular healthcare visits.   
Both the Diagnosed Ill and Medically Managed groups have medical diagnoses 
yet sort into different groups, attesting to the influence of perceived health status.  
Although group differences could be ascribed to differences in the mean number of 
diagnoses for the DI and MM groups (4.40 versus 2.75, respectively), in both groups all 
persons had medical diagnoses, the range in number of conditions was similar (nine 
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versus ten, respectively) and their mean ages were similar.  It is possible that the 
nature/type of diagnoses differed between these groups, or that perceived risk contributed 
to perceived health.  
 
Perceived Risk 
 
Risk Perception, a concept explored in prior DTC genetic testing studies as a 
motivating factor or concern
12,17,45
, was examined in relationship to perceived health 
status in the current study.  Risk perception was found to be significantly different across 
health status groups (see Table 5.3), being greatest in the DI group.  From the distribution 
of groups and conditions in Figure 5.1, it appears that both perceived health status and 
medically defined health status contribute to risk perception.  Two study findings suggest 
that perceived health status may be an initial, greater and/or at least meaningful influence 
for pursuit of genomic testing.  The Healthy group, with perceived good health and no 
medical diagnosis, had the lowest perceived risk.  This makes sense and does not 
necessarily imply the influence of perceived health status.  However, the fact that the 
MM group had a significantly lower perceived risk than the DI group supports the 
potential influence of perceived health status (good in MM).  The Health in Question 
group, albeit small, were youngest (mean age 30.3) and were without a survey-specified 
medical diagnosis, yet rated their health as fair or poor and had the highest mean (4.57) 
for conditions at perceived increased risk.  These persons were not identified by text 
query of reasons for pursuit of genome testing, yet cursory examination of related text 
fields identified statements such as: “…interested in Genomics, and think it is a good idea 
given my medical history…” and “I chose … genetic testing because of some health 
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issues I am experiencing”.  Entries also included mention of desire for risk identification, 
condition-specific or prevention-related information.  A qualitative study involving this 
HQ group and examination of all study population text answers may identify others in 
this group, shed light on this perplexing issue and contribute to understanding health 
factors relevant to effective and individualized healthcare. 
Since the nature of the groups examined the combined effect of both health status 
parameters, in relation to perceived risk, correlations were done to examine these 
parameters separately.  Perceived risk was weakly correlated (.272) with medical 
diagnosis status alone, whereas perceived health status alone or combined with medical 
diagnosis status demonstrated moderate correlations (.301 and .326, respectively).  These 
weak or moderate correlations are consistent with other findings.  Of the persons (33) 
indicating the highest number of conditions at increased risk (10-17), the majority (23) 
had only one to three medical diagnoses.  Of the persons (65) with the highest number of 
medical diagnoses (7-10), only one indicated more than eight risk conditions.  These 
results support that perceived risk and perceived health status likely influence each other 
(are positively correlated), yet also indicate that neither equates with nor substitutes for 
the importance of integrating the other.  Further studies may be helpful in clarifying risk 
perception relevant to these health status groups, and perceived health status alone, such 
as disorder-specific perceived liability/risk, positive family history and/or the results of 
genomic testing.  
Finally, it is noteworthy that regardless of health status group, the major targets of 
perceived increased risk were heart disease, diabetes, skin cancer (melanoma), and breast 
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and prostate cancer.  These concerns may reflect positive family history, personal 
experience, genome laboratory information, public education, the influence of mass 
media, or interest in common diseases 
11
.  This knowledge has relevance for clinicians, 
researchers, personalized healthcare and genomic testing laboratories, relating to 
readiness and timing of educational efforts, addressing screening and management of risk 
factors, and discussion with potential pursuit of genomic testing.    
 
Reasons for Pursuit of Genome Testing & Health Values 
 
Across all three health status groups, at least 69% of participants assigned 
importance to ten of twelve reasons for pursuit of genome testing (see Table 5.2); over 
81% indicated the desire to improve health as important.  The reasons posed to 
participants for assessment of their interest were consistent with those identified in other 
DTC genome testing studies, as was the finding that the majority assigned importance to 
the desire to improve health 
10,12,46
.  This response implies a perceived or expected 
connection between genomic information and improving health.  The lowest levels of 
importance were associated with family members using personal genomics, and learning 
about genetic make-up without physician involvement.  The former suggests that family 
pressures were not a major issue (although relevant for over half), and while the latter is 
consistent with previous research demonstrating individual interest in collaborating with 
healthcare providers
11
, 58-62% of participants rated this item as important.  Possible 
explanations include the inherent nature of persons who independently pursue genome 
testing, public concerns about genetic discrimination (e.g., if genomic information gets 
into their health records)
47
, or that genomic information is valued and cannot be obtained 
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through their healthcare provider.  Patients and providers could benefit from open 
discussion to foster better understanding of health values, goals, concerns and utility of 
genomic information toward personalized and more effective healthcare
48
.  
The Diagnosed Ill and Medically Managed groups, despite having a medical 
diagnosis and age in common, demonstrated statistically significant differences on four of 
five reasons for pursuit of genome testing (see Table 5.2).  These items related to 
immediate medical risks (specific disease, drug response) or future planning (for self or 
family).  In contrast, the Medically Managed and Healthy groups both with perceived 
good health, who were statistically different in age, income and diagnostic status, were 
not significantly different on importance for three (of the five reasons) for pursuit of 
testing.  These reasons involved future plans, identifying disease risk and entertainment 
value, suggesting less immediate perceived health needs.  
The most dramatic finding was that all three groups were significantly different (p 
< 0.001) on the two survey questions about importance of finding out about personal 
response type to different medications (see Table 5.2 and Table 5.4).  These results 
demonstrate internal consistency, and also support potential clinical relevance for this 
study’s health status categorization.  The DI group had the highest percent interested in 
drug response information, followed by the MM and then the Healthy group; however, 
even that lowest encompassed 85.3%.  The DI’s highest level of importance may be 
because that they have the most to gain if genomic information helps in personalizing 
more effective treatment or avoiding drug-related complications.  This reasoning suggests 
a greater influence of diagnostic health status, as opposed to perceived health, for 
  
136 
 
individual importance of learning their drug response type; however, this would not 
explain why the MM group had a lesser percentage than the DI.  These results, and the 
lower percent of importance for the H group, support the influence of both medical 
diagnosis and perceived health.  This assessment is also supported by the significant 
difference (p < 0.001) across all three groups for interest in learning about the risk for 
other diseases.  Overall, these findings demonstrate the personal value and importance 
that individuals place on personalized drug-related information
17
, providing an insight 
relevant to healthcare providers, policy developers and genome testing laboratories.  
The Diagnosed Ill group also assigned the highest importance to receiving 
information about personal risk for a specific disease, and creating a better plan for the 
future (see Table 5.2).  The desire for genomic information about an existing disease may 
be surprising, yet is supported by another study
49
, although the reasons are not clear.  Do 
these people hope that genomic information will clarify or assign cause for their 
condition, foster targeted treatment to ameliorate disease, and/or have prognostic value?  
Or does this simply reflect a fundamental desire of people to value “answers”.  These 
potential reasons could interrelate with importance of creating a better plan for the future.  
The DI group (e.g., if facing mortality) may view genomic information as important to 
family, consistent with their assigned importance to genomic information for their 
children (82.4%).   
Finally, the MM and H groups also had a high percent assigning importance to 
personal risk for disease (see Table 5.2).  Participants across all groups indicated creating 
a better plan for the future as important, yet the reasoning, values or goals behind those 
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similar choices may be very different.  This information may be useful to clinicians.  For 
example, for the DI group, planning for the future may warrant discussion of DNA 
banking, whereas, for the perceived healthy groups, there may be a desire for early risk 
identification, maintaining and promoting health, the issue of personal utility or value, 
potential for motivating health behaviors, and/or implementing prevention measures.  
Values Pre-testing:  Although there was no specific health values question, ten 
values-related items allowed some capture of this concept with inferences (see Table 5.4).  
Interestingly, the nature of these value results paralleled the group findings for reasons 
for pursuit of genome testing.  In four out of five items, the DI group was significantly 
different from the others.  The one exception was the Healthy group for value (higher) of 
carrier status information, possibly due to the questionnaire’s parenthetical reference to 
pre-pregnancy planning and the group’s significantly younger (<0.001) mean age.  Both 
the Healthy and Medically Managed groups were similar (within 1.2% of each other) and 
had lower frequencies (yet were 79.5–83.6%) than the Diagnosed Ill group for 
considering how well results predict disease and agreement that what they (will) learn 
from genome testing can help reduce the risk of getting sick.  This again seemed to depict 
a tendency for the DI group to be interested in their disease state, treatment and avoiding 
illness.  
Post-testing:  The direct question of whether genome testing was valuable scored 
highest across all groups, with no statistically significant difference.  All groups also 
indicated all values-related items as important; however, groups demonstrated 
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statistically significant differences by t-tests involving genomic information as 
influencing future health management and using it to improve health.   
In summary, the study findings support personal health values as relevant to 
pursuers of genome testing, and genomic information as having personal health value.  
Despite this uniformity, the distinctive health status groups created in this study allowed 
identification of statistically significant differences on noted values items based on 
perceived health status (where groups with medical diagnoses differed).  Although results 
indicate genomic results have value, without further qualitative study, there is no way to 
confirm assumed meaning or associated personal translation into health actions. 
 
Study Issues and Limitations 
 
The two surveys used for this study were based on validated instruments and 
measures with demonstrated reliability, yet issues that limited results or interpretation 
were the following:  1) the surveys were lengthy, potentially explaining the attrition 
between the first and second surveys; 2) perceived redundancy or complexity in certain 
sections, e.g., the second set of twelve risk related conditions with a less than 40% 
response rate; however, it was apparent that some participants neglected to answer items 
when their perceived risk was not increased; 3) potential overlapping answer options, 
e.g., as encountered by persons without children, when offered both not applicable and 
not interested regarding interest in testing for children; 4) confusing terminology or 
phraseology—either technical, colloquial or with more than one possible interpretation, 
e.g.,  “genomic information can help reduce the risk of getting sick” and “learning about 
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‘traits’”; and, 5) interpretation of multiple choice or text answers by limited analysis or 
assumed meaning, i.e., curiosity had different meanings.   
Study specific issues arose.  Both surveys included questions relevant to 
examining this study’s subjective concepts (i.e., perceived health status, risk perception 
and health values); however, these items were not repeated thus precluding pre- and post-
testing comparison.  The study design did not have a control population; all study 
participants had pursued genome testing.  Data analysis was limited in that most variables 
were categorical and postulated to be in an interdependent relationship (as opposed to 
independent/dependent).  Health status groups, created by dichotomizing perceived 
health status and existence of a medical diagnosis, may have restricted numbers in the 
Health in Question group (that was too small to include in analysis). 
Despite these considerations, the unique nature of this naturally occurring 
population of persons who independently pursued genome testing, without involvement 
of their healthcare providers or researchers, allowed examination of subjective health-
related factors as potential influences on self-initiated individual health actions (i.e., DTC 
genome testing).  
 
Conclusions 
 
Perceived health, alone or in combination with medical diagnostic status, is able 
to distinguish or is correlated with overall personal health status, risk perception and 
health values.  This knowledge may facilitate integration of individual health perception 
and health values into healthcare in order to collaboratively assess, prioritize and provide 
personalized, efficient and cost-effective healthcare services.  This approach is 
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compatible with the Health Capability framework (basis for this study) and other 
healthcare models that recognize individual health values, ability for personal choices and 
responsible support of independent consumer actions including genomic testing on behalf 
of their health needs and goals.  
Existing perceived health status research is primarily structured from an illness or 
biomedical framework, with outcomes measures such as delay in mortality, reduced 
morbidity, improved functional status or cost/benefit ratios.  Little research exists 
involving healthy persons (except as controls) who seek health promotion 
services
21,22,50,51
.  These persons may be viewed as the worried well and/or as draining 
limited healthcare resources
19
.  On the other hand, consistent with public education 
efforts promoting healthy behaviors, the value of screening and recognizing risk factors, 
these people may represent persons interested in maintaining and promoting health and/or 
having legitimate health problems that do not meet diagnostic criteria. 
Perceived heath status is integral to overall health status. It may differentially 
influence healthy persons, as opposed to persons as they age or health declines when 
biomedical status may become more urgent and motivate action.  This reasoning could 
also support health-related actions of relatively healthy persons as they face acute illness 
or anticipated health risk.  This study population included 20% healthy persons, most of 
who would not otherwise have come to the attention of the healthcare system.  What 
motivates these persons, as well as the other 80% with medical diagnoses, was explored 
in the context of personal health perception, values and self-initiated health action vis-à-
vis genomic testing in hopes of informing gaps in the current healthcare system. 
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Perchance we are not seeing some worthwhile outcomes (e.g., health behavior change) 
because we are focused on the quantitative outcomes (delay of mortality, lesser morbidity 
or measurable functional status) rather than the goals and values of the individuals and 
the behaviors they deem worthwhile.  Perhaps we could get better outcomes by 
measuring an individual’s valued outcomes, and at the same time make more efficient use 
of human and economic healthcare resources
52
. 
Despite study limitations, genomic information is supported as both an individual 
health value and as having perceived value for improved individual perspective on 
personal health status, perceived control of health, ability to decrease the risk of getting 
sick and the ability to improve health and influence future health management.  Research 
attests to the fact that users of DTC genome testing desire to discuss and share test results 
with their healthcare providers
11,17
.  So why do we not take advantage of this interest to 
work collaboratively in partnership with our patients and the healthy public in decisions 
about genome testing?  Why do we indirectly support and promote individual 
independent pursuit of this testing? 
The underlying message of this study’s findings is that practitioners and patients 
could likely benefit from integrating three simple questions into routine clinical practice.  
These questions are the following:  1) “In general, how would you rate your health?”  
Then ask, “Why?”  2) “What is your greatest health concern, need or value?”  And, 3) 
“What is your health goal?”  From this, the practitioner can collaboratively determine an 
effective and practical plan.  As far as genomics, that would be the next question, as 
genomic screening for risk becomes part of routine healthcare practices.  Personalized 
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healthcare integrating genome testing for everyone is on the horizon whether that is via 
the DTC route, an indirect path or new approaches in conjunction with healthcare 
providers. 
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CHAPTER VI 
 
EXTENDING THE HEALTH CAPABILITY CONCEPTUAL FRAMEWORK: 
INDIVIDUAL PERCEIVED HEALTH STATUS AND HEALTH VALUES 
 
 
Introduction 
 
The main research question addressed the motivations for individual independent 
pursuit of genome testing.  The hypotheses tested whether individual perceived health 
status (including perceived risk) and personal health values were influencing factors.  
Chapter II provided the literature review and discussion of these concepts.  Health 
Capability, the conceptual framework, provided the basis for the proposed concept 
mapping and relationships.  The rationale and relevance of this model for this research 
was presented in Chapter III.  The major tenets of this framework included individual 
health values, goals and health agency (supporting individual choice), the existence of 
internal and external influencing factors consistent with research concepts and variables, 
and its adaptability for extension to prevention and health promotion for DTC genome 
testing.  Perceived health status, the key concept/construct for this research, was 
addressed in Chapter IV in a systematic review of the literature.  Also included in this 
literature review was a discussion of instruments and approaches used to capture and 
measure this concept/construct.  Chapter V presented the research study, methodology, 
results and discussion, limitations and identified areas of need for future research and 
clinical applications. 
Chapter VI will present the impact of the study findings related to research 
hypotheses and enhancing and modifying the proposed Health Capability concept 
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mapping.  Plans for additional research to clarify and characterize components of 
perceived health status will also be presented.  Finally, based on the outcomes of this 
study, the need for future research will be presented.  
 
Background 
 
This dissertation research study examined health status, dichotomized by 
perceived health status and a biomedical view of health status (existence of a medical 
diagnosis), in DTC genome testing users.  The primary hypothesis was that discrepancies 
exist between the individual and biomedical view of health status.  This hypothesis was 
supported by the results of categorizing participants into health status groups that 
confirmed the existence of the proposed four mutually exclusive health status groups.  
These groups included the two discrepant groups, specifically persons with one or more 
medical diagnoses who rated their health as good to excellent, and healthy persons who 
rated their health as poor or fair.  This latter group supported existence of the “worried 
well” (Garfield, 2006).  A healthy group was also identified, as persons without a medical 
diagnosis and rating their self-health as good to excellent.  Each of these groups raises 
questions as to differences in the reasons (motivations) for pursuit of genome testing, 
health values and distinguishing characteristics.  Findings also have relevance for 
prioritization in clinical practice, individual health behaviors, cost-effective healthcare 
services and research.   
The Health Capability model (Ruger, 2010) was used as the conceptual 
framework for this study.  This is a relatively young paradigm without an operational 
model or measurement instrument and little applied clinical research.  The unique 
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contribution and potential for the Health Capability framework is its commitment to 
individual health values, support for individual health goal achievement, research at the 
individual level with extension from there to the population level, and its adaptability for 
application to prevention and independent individual action in pursuit of heath goals (i.e., 
genome testing).  
 
Health Capability:  Proposed Concept Mapping—Revised 
 
In Chapter II, concept mapping was proposed to operationalize Health Capability 
(Ruger, 2010) for this study and evaluate its use for this dissertation research.  It was also 
intended that this model be applicable to other potential clinical and research use in the 
context of a theoretical framework committed to physician (practitioner)—patient 
(individual) partnership, recognition of individual health values and goals, and support 
for prevention at the individual as well as public health levels.  The original concept 
mapping has been updated and revised based on the results of the dissertation research 
(see Figure 6.1, including Pearson correlation values and highlighting of study concepts 
as discussed below).  Although the research hypotheses did not include one specific to 
Health Capability, the fact that this model served as the framework for study concepts, 
for proposed and tested relationships, and for adaptation for prevention and health 
promotion vis-à-vis DTC genome testing, coupled with the study findings (presented in 
Chapter Five and discussed further in this chapter), is consistent with initial assessment 
and support for its use and further study in DTC genome testing research.  
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Health Status 
 
This concept previously included “health functioning” in its title since both terms 
were included in the Health Capability profile (Ruger, 2010).  However, health 
functioning reflects only limited measures of health status, usually in relation to disability 
or the ability to perform activities of daily living (Lachman & Agrigoroaei, 2010; 
Schiffman, Jacobsen, & Whitcup, 2001).  Thus, Health Status (green highlight) was 
modified to encompass three measures of health (see Figure 6.1): the two components  
(blue highlight) specified in the Health Capability profile (Ruger, 2010), plus the addition 
of perceived health status (yellow highlight).  
 
1. Functional:  Maintained as a component of health status, including its 
measurement (e.g., by the SF-36 (Ware, 2009; Ware & Sherbourne, 1992). 
 
2. Health Conditions and Risks (objective):  Maintained as a component of 
health status, including its measures (e.g., vital signs, EKG, CBC, screening, 
etc.).  The term objective is included in order to distinguish this from the 
individual (subjective, perceived health) component.  The Pearson correlation 
coefficient (.272), based on results of this research, has been added to the 
relationship line between Health Status (the construct, represented by the 
research Health Status groups) and the biomedical measure of health status 
(existence of a medical diagnosis).  Although the correlation analysis was 
found to be statistically significant, the large study population (N = 1455) may 
have contributed to inflating its apparent impact since the correlation value 
itself (.272) is considered only weakly positive. 
 
3. Individual Perceived Health (subjective):  This component was added as part 
of the proposed concept mapping prior to the completion of the dissertation 
research.  It is consistent with Health Capability’s philosophical recognition of 
an individual’s view and values for their health, as well as its respect for an 
individual’s view and values for their health, as well as its respect for an 
individual’s assessment of their health as evidenced by inclusion of measures 
of self-reported health functioning.  However, measures of functional health 
status and biomedical health status cannot capture the totality of an 
individual’s perceived health, what is of personal relevance and value, and 
what impacts actions and outcomes.  Studies of individual perceived health 
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have demonstrated its significant and unique contributions in outcome studies 
of mortality and morbidity (Benyamini & Idler, 1999; Idler & Benyamini, 
1997).  However, there is little research from a prevention focus, and the 
limited research that exists is population and disease/illness oriented (Chern, 
Wan, & Pyles, 2000).  This was discussed in the review of literature in 
Chapter Four.  Assessment of health status from the individual perspective, 
and awareness of personal health values, has been recommended as an integral 
component for routine healthcare practice essential to the ability to evaluate 
meaningful outcomes (Barr, 1995).  Thus, based on the literature review, 
previous studies and the current study results that support the distinct nature of 
individual perceived health status (yellow), and its association with the overall 
construct of Health Status (green), the relationship line between them was 
changed to solid (from dashed) and the relevant correlation values were 
added. 
 
 
Perceived Health Status (Hypothesis 1) 
 
Perceived health status, the subject of literature review as presented and discussed 
in Chapter IV, was captured, measured and validated in research either by a single Likert-
type item or a measurement instrument (Benyamini & Idler, 1999; Idler & Benyamini, 
1997; Leung, Luo, So, & Quan, 2007).  An instrument to assess perceived and targeted 
health status is frequently used in studies involving disease, mortality, morbidity, 
disability or interventions (Bardsley, Astell, McCallum, & Home, 1993; Salaffi, Stancati, 
& Carotti, 2002).  The single item is preferred for brevity and where an overall 
perspective of perceived health status will achieve the study’s need or intent.  Based on 
the PGen survey and database, perceived health was represented by a single item in the 
dissertation research.  It was used to create Health Status groups combining both the 
subjective individual perception of health with an objective biomedical perspective of 
health (existence of medical diagnosis).  Hypothesis 1, that discrepancies existed between 
these two perspectives, was confirmed by identification of participants within all four 
  
153 
 
health status categories.  This result supported the integration of perceived health status 
as a separate, contributory subdomain of Health Status.  
 
Perceived Health Status:  Proposed Components 
 
Perceived health status was proposed to be comprised of seven subdomains 
(components; see Figure 6.1) based on existing genetics, genomics and perceived risk 
research and literature (Cameron, Sherman, Marteau, & Brown, 2009; Carere et al., in 
press; R. Green & Roberts, 2012b; Heshka et al., 2008; D. J. Kaufman et al., 2012; Orom 
et al., 2012; Valdez, Yoon, Qureshi, Green, & Khoury, 2010).  The subdomain of primary 
focus, in conjunction with the examination of individual health status and personal health 
values, was perceived risk.  This component is discussed below, as are variables relating 
to limited components of other perceived health status subdomains, together with the 
implications based on the study findings.  These subdomains are:  
 
1. Physical Factors:  Discussed below 
 
2. Mental/Psychological Factors:  Relate to mental, emotional or psychological 
health status, including any existing medical condition that the individual 
views as compromising to his/her health 
 
3. Familial Factors:  Relates to health or risk status based on ancestry, ethnicity, 
race, condition or potential medical problem that the individual views as 
impacting (or potentially) his/her health risk (e.g., a condition that tends to run 
in the family) 
 
4. Genetic Factors:  Relates to existence (per individual report) of a known 
specific genetic disease, mutation, or genomic risk associated with a mutation 
in oneself or one’s relative 
 
5. Environmental Factors:  Includes exogenous risk factors over which the 
individual has little or no personal control, such as those existing in one’s  
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place of employment, geographic area, and/or as reportedly prescribed or 
medically necessary (e.g., per one’s healthcare provider) 
 
6. Lifestyle Factors:  Includes behavioral factors over which the individual has 
personal control, such as smoking, alcohol consumption, use of illegal, non-
prescription or self-initiated drugs (e.g., not prescribed by one’s healthcare 
provider) 
 
7. Perceived Risk Factors:  Discussed below 
 
 
Physical factors:  In the proposed concept mapping, physical factors related to 
physical health status, including any existing medical condition that the individual 
viewed as impacting or compromising to his/her health.  This subdomain is incorporated 
in all three measures of health status (functional, biomedical and perceived).  The focus 
discussed here is limited to assessments and comments in the context of perceived health 
status.  Physical health is known to impact one’s perceived health, yet physical health 
status is also related to biomedical health and existing diagnosis, and functional health 
status, both of which also contribute to quality of life considerations (Lachman & 
Agrigoroaei, 2010).  This study was limited to the examination of biomedical health 
captured as the existence (or not) of one or more medical diagnoses, and was compared 
with and noted to have distinctions from, an individual’s perceived health status.  To 
what extent perception of physical health status contributed to one’s overall perceived 
personal health status is not known and could not be characterized/quantified by this 
study.  However, given the finding that the health status groups with medical diagnoses 
had significantly different (higher) perceived risks (number of conditions at increased 
risk), and that previous research supported the importance of functional health (Haseen, 
Adhikari, & Soonthorndhada, 2010; Lachman & Agrigoroaei, 2010), it may be that 
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perceived physical health is more relevant when it is perceived as compromised or urgent 
(as opposed to when one is healthy) (Mann, de Ridder, & Fujita, 2013).  In this 
dissertation, related to Hypothesis 3, age was examined in association with health status 
groups, and separately, with individual perceived health status.  Statistically significant 
differences between health status groups supported rejection of the null Hypothesis 3 that 
there would be no difference.  However, significant differences were limited to 
combinations with the Healthy group, whose mean age was 37.5, in contrast to 51.2 and 
50.1 in the Diagnosed Ill and Medically Managed groups, respectively.  These results are 
consistent with other studies that demonstrate conflicting results related to age and 
pursuit of DTC genome testing (Bloss et al., 2010; Cherkas et al., 2010).  It is also 
noteworthy that in the overall study population, individual age was not correlated with 
perceived health status.  This latter finding lent support to the position that physical 
health status may be sufficiently addressed by the combination of functional and 
biomedical health status measures.  Further, if one’s physical health is not compromised 
or of concern, it may be that its influence or contribution to perceived health status 
essentially becomes negligible.  This would be relevant for future research to understand 
individual motivations for health actions.  
Perceived Risk (Hypothesis 4):  Based on the previous literature review and 
studies incorporating perceived risk (or perception of risk) related to genomics (Acheson 
et al., 2010; Heshka et al., 2008; D. J. Kaufman et al., 2012; McBride et al., 2009; 
Sjoberg, 2000; Tarr et al., 2014) performed to develop Health Capability, the concept was 
defined as individual recognition or appreciation of real or believed vulnerability, 
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compromised health status and/or likelihood of a disease(s), disorder(s) or condition(s) 
(specific or in general), as either increased relative to others, or existing to an extent 
beyond that acceptable to that individual.  This definition reflects the individual’s 
subjective perspective and values, consistent with Health Capability and the nature of 
survey data used in this dissertation research.  Perceived risk was represented in the 
dissertation on an individual level as the sum of perceived risks (likelihood to develop) 
for twenty-four survey-specified conditions.  Rejection of the null Hypothesis 4 that 
projected no significant difference between health status groups was supported by the 
finding of significant differences between health status groups by t-tests.  Separate 
correlation analyses of perceived risk identified the highest correlation (.326) with 
perceived health status, the lowest (.272) with biomedical health status, and a middle 
value (.301) with the combined health status groups.  These results supported a 
relationship between perceived risk and individual health status, both from objective 
criteria and subjective individual perspectives, warranting inclusion of both as relevant to 
individual health status and assessment. 
Research studies have examined and confirmed perceived risk as an interest, 
reason or motivator for individual pursuit of DTC genetic or genomic testing (Goldsmith 
et al., 2012; Gollust et al., 2011; David Kaufman, Bollinger, Devaney, & Scott, 2010).  
Another study determined that persons who pursued DTC genome testing were most 
interested in the condition or diagnosis they had (Meisel et al., 2013).  However, 
perceived risk has not been studied as to its relative contribution among other personal 
(subjective) motivators for pursuit of DTC genome testing, or as to its association with 
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one’s combined perceived and medical diagnostic health status (as supported in the 
current study).  This study found perceived risk to be among the highest for the same 
medical conditions (i.e., heart disease, diabetes, skin cancer, breast cancer, prostate 
cancer, and high cholesterol), across all health status groups, ranging lowest in the 
Healthy group, to intermediate in the Medically Managed group, to highest in the 
Diagnosed Ill group.  These conditions are consistent with risk concerns identified in 
prior DTC genome testing studies [e.g., heart disease (Gollust et al., 2011)], and 
accounted for risk concerns in a minimum of 13%, and a maximum of 48%, of persons 
within the health status groups.  Whether or not concern about a single condition, or a 
collective sum of perceived risks, is a significant contributor to pursuit of DTC genome 
testing remains uncertain.  Furthermore, this issue raises the question of a threshold of 
tolerance for risk or need for information, that influences health-related action (i.e., DTC 
genome testing).  Studies are needed to address these potential influences, as well as to 
explore the possibility of triggering events, needs or perceptions.     
An important realization that derived from this dissertation process and the 
outcomes of the research related to perceived risk versus perceived health.  It is 
noteworthy that, with the exception of perceived risk, the sub-domains of individual 
perceived health proposed in the concept mapping all related to both perceived health and 
to perceived risk (components as identified by the literature review).  However, since the 
correlation between them is at most a moderate positive (.326), they are neither mutually 
exclusive nor would these results suggest the use of one as more important or as a 
surrogate for the other.  This is an important finding relevant to appreciating the gaps and 
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potential biases in the healthcare literature, research and clinical practice.  A primarily 
risk focus reflects a disease/illness model and minimization or lack of health related 
freedoms and choices if one is deemed healthy (i.e., not sick) (Boenink & van der Burg, 
2010).  Perceived health is typically not the focus or included in research.  If it is 
included, it is generally disease focused or captured by a single question, reported as 
general frequencies with little other application (Barr, 1995; Carere et al., in press; 
Lichtenstein & Thomas 1987; Miilunpalo et al., 1997).  Thus, not only does this indicate 
a gap in research and understanding of the potential impact or influence of perceived 
health status, but it also raises awareness and questions related to the evaluation of and 
healthcare priorities for healthy, or seemingly healthy, persons.  This includes the need 
for further study of the “worried well”, and the extent of their numbers that may be 
obscured within other health status categories or non-responses.  It also includes the goals 
and values of healthy persons, with the potential for adjusting healthcare priorities, 
allocation and type of services, and contributing to resource-effective health promotion.  
These issues were discussed in Chapter V. 
 
Reasons for Pursuit of Genome Testing and  
Socio-demographics (Hypotheses 2 & 3) 
 
 The reasons for pursuit of genome testing, associated with Hypothesis 2, 
interrelate with health values as well as health goals, and are addressed in the Discussion 
section.  Socio-demographic characteristics, and support for or rejection of Hypothesis 3, 
are considered as relevant in the following sections.  
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Health Values (Hypothesis 5) 
 
Health values, addressed in the review of literature included in Chapter II, were 
operationalized in the dissertation research using PGen survey Likert-type questions 
(from both the pre-testing and the two week post-testing surveys) relating to items of 
individual health importance, interest, consideration and/or value.  The study results 
confirmed an association between Health Values and Health Status groups.  Two of the 
five health values items (importance of genome results for future health management, and 
for health improvement) were significantly different by t-tests between health status 
groups.  This finding supports rejection of the null Hypothesis 5 that there would be no 
difference in health value of genomic information between health status groups.  The 
results indicate that there is a distinctive contribution from (subjective) perceived health 
as opposed to the (objective) existence of a medical diagnosis (i.e., if unsupported, all 
persons with a medical diagnosis, or all persons with perceived good health, would not be 
significantly different).  On the other hand, the fact that all health status groups:  1) were 
not significantly different on three of the five items; 2) all rated all items as having at 
least some value/importance (means ranging from 3.46 to 4.16, with 3.0 being neutral 
and 5.0 being strongly agree); and, 3) uniformly rated the highest for genome results as 
being valuable to their health [consistent with previous research (McBride et al., 2009)], 
supported the relevance of health values to pursuit of genome testing, and potentially to 
other self-initiated health behaviors.  The comparison of pre-testing expected health value 
of genome test results with post-testing individual value based on actual results was not 
possible since the same measures were not repeated.  However, the findings do contribute 
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to supporting individual health values as a primary component of the proposed 
operationalization of Health Capability, and its applicability to DTC genome testing 
research.  
Future study of the combined contributions and effects of individual perceived 
health and health values on individual health goals and behaviors is supported by the 
current results, as well as other research (Shmueli, 1999).  A future study will examine an 
individual’s perceived health status combined with health values (i.e., the items that 
differentiated health status groups in the current study), in relation to an individual’s 
intended behavior change as stated at two weeks post testing compared with their stated 
health behaviors as reported at six months.  
 
Study Limitations 
 
One limitation of this study is that the correlation coefficient between overall 
Health Status and Individual Perceived Health was based solely on the health status 
groups for the former, and the limited measure of perceived risk for the latter.  Despite 
this limitation, a relationship was demonstrated (see Figure 6.1; the line between them 
has been changed to solid & non-directional). 
Limitations also exist related to the fact that this study involves secondary 
analysis of data from the original PGen research surveys.  Multiple-choice questions were 
framed from, and/or provided answer options supported by, results of previous DTC 
genome testing research studies; however, that approach did not allow for other possible 
individual responses.  Another limitation in the current study was the inability to evaluate 
individual health values pre-testing since that concept and related questions were not 
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included in the pre-testing survey.  Despite these limitations, the PGen survey questions 
and data did include questions in which relevant individual answers and qualitative data 
could be captured.  Targeted questions with text answers were queried for keywords that 
confirmed, on a preliminary basis, the existence of different individual perspectives 
related to reasons for testing and interpretation of terminology used (e.g., curiosity).  
These subjective text answers coupled with the ability for a mixed qualitative and 
quantitative approach to data analysis provided a unique dimension not included in 
existing research (Bloss et al., 2010; Goldsmith et al., 2012). 
Generalizability was also a relevant issue from two perspectives.  The current 
study population, participants in the PGen study, demonstrated socio-demographic 
characteristics consistent with previous DTC genome testing users research (Bloss et al., 
2010; Goldsmith et al., 2012; McGuire et al., 2009).  Thus, study results are likely 
generalizable to other DTC genome testing users.  On the other hand, this study 
population, consistent with the previously cited studies, is different from, and is not 
generalizable to, the general population.  Specifically, these cited studies of DTC users 
have found that participants tend to have higher levels of education; have higher incomes; 
be Caucasian; be professionals, scientists, in academia or employed in mid to upper level 
jobs; and indicate their perceived health as good.  Importantly, however, as the cost of 
DTC genome testing decreases, public awareness increases, marketing and new genome 
related testing services are offered (e.g., prenatal sex typing), NIH funded research exists 
for new approaches to early risk identification and/or health promotion using genomic 
screening (e.g., in newborns), FDA regulatory authority has gaps in controls of DTC 
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laboratory tests, and/or genome testing (or screening) further demonstrates clinical utility, 
there could be a significant increase in the number of individuals pursuing genome 
testing, as well as the socio-demographics of DTC testing users.  
 
Discussion and Conclusions 
 
Perceived health status of the DTC genome testing users in this study spanned all 
five Likert-scale choices from excellent to poor, with the majority (1,235/1,455) rating 
their health as good to excellent, regardless of medical diagnostic status.  However, by 
sorting the study population into four mutually exclusive health status groups based on 
inclusion of perceived health status, distinguishing characteristics emerged.  Persons with 
a biomedical diagnosis and perceived poor or fair health expressed higher levels of 
interest for genomic information of immediate personal relevance, or for their family, i.e., 
about their current medical condition, other health risks and response type to different 
medications.  In contrast, study respondents indicating their health as good to excellent, 
whether or not they had a medical diagnosis, expressed greater interest in genomic 
information related to future health, risks and ability for prevention (although also 
interested in the previously noted health information).  Thus, perceived health status was 
associated with the type of genomic information sought, the percent indicating an item as 
important, and interest in immediate versus future use.   
Health values were supported as important to the DTC genome testing study 
participants.  All three health status groups assigned the highest scores to genomic 
information as being valuable to health (see Figure 6.2).  In addition, group means on all 
other health values items were in the direction of having value, with some items  
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Figure 6.2:  Genome Test Results—Value To Respondents’ Health. 
 
 
 
KEY:  **Statistical significance.  Set of bars at right is based on maximum of 3. 
 
 
extending into the range of extremely important/valuable.  Three observations are 
noteworthy.  The highest mean scores for all health values items occurred in the 
Diagnosed Ill group.  This finding suggests that persons with medical diagnoses and self- 
rated fair or poor health may perceive the greatest potential for genomic information to 
offer some help for their current health.  Second, all groups scored similarly (high) 
related to genomic information as providing a better perspective on their health status and 
for feeling like they had more control of their health.  This supports that DTC genome 
testing users tend to value an active role in health related decisions and ability to take 
charge of their health.  Third, all respondents indicated, in a positive direction, that 
genomic information can be used to improve their health.  Whether or not that is accurate 
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in the context of clinical utility, it is seen as valuable for personal utility.  This 
information has direct relevance to healthcare providers, prioritization of services, 
appreciation for what is meaningful to consumers, targeting health education (and needs) 
and collaborative decision-making.   
This study’s survey requested participants to indicate the importance of twelve 
reasons for pursuit of DTC genome testing, based on motivations identified by previous 
research as discussed in Chapter II.  Some of these reasons overlap into the realm of 
individual health values and health goals.  For example, close to 100% of respondents in 
all health status groups indicated that their pursuit of genome testing considered obtaining 
(the goal of) personal health information (see Table 5.2, Chapter V).  This goal is further 
supported by the relatively high percent among all groups indicating the desire for 
genomic information about their response type to medications.   
The research Hypothesis 2 (null), stating that there would be no difference 
between health status groups related to reasons for pursuit for genome testing, was 
rejected for some reasons (e.g., finding out response type to different medications) and 
was supported for others (e.g., curiosity, and family members using personal genomics).  
An important consideration, however, is that on several reasons for pursuit of genome 
testing (e.g., genomic information related to personal risk for disease, for future children 
and the desire to improve health) over two-thirds of persons in all groups scored the 
reasons as of interest.  These findings not only indicate an explanation for apparent non-
significant differences between groups (since the majority in all groups were interested), 
but suggest that DTC genome testing users are interested in goals associated with 
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prevention and health promotion.  It is also relevant to note that although more than 90% 
in each group responded that curiosity was involved, with that reason potentially viewed 
as having no clinically relevant health value or goal (and similar regarding pursuit of 
testing as fun and entertaining), an initial review of text answers of reasons for pursuit of 
genome testing attributed very different uses or meanings to curiosity.  This study finding 
highlights a dimension important to clinicians and researchers concerning the structure, 
content and selection of survey questions, but also their interpretations.  
The results of this study demonstrated that perceived health status distinguished 
health status groups and made a significant difference in individual reasons for seeking 
DTC genome testing, goals for genomic information and in risk perception.  Perceived 
health status served as a complement to, and at times evidenced a higher correlation, than 
biomedical health status (e.g., for perceived risk status).  The importance of individual 
health values was also demonstrated in self-initiated genome testing users.  These 
findings lend support for use and testing of the Health Capability conceptual framework 
as a model for integrating individual health values and goals into healthcare services, 
delivery and policy directions.  This study’s results contribute to furthering understanding 
of the influence of perceived health status and its potential for application in the context 
of early identification of risk, prevention and health promotion.  The modified concept 
mapping provides a basis for further study of individually relevant health concepts and 
factors that may influence health behaviors, such as self-initiated health action (e.g., DTC 
genome testing, or exercise program).  It also facilitates the ability to test for existence of 
triggers, a threshold effect, or factors impacting readiness for health information and 
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commitment to healthy behaviors.  This knowledge has the potential for more effective 
strategies for provision of healthcare and use of its limited resources.     
 
Future Research 
 
The findings of this study indicate the need for research in three areas.  First, there 
is a need for research and strategies spanning beyond traditional models of healthcare to 
incorporate prevention, as well as integrating subjective individual perceived health, 
personal health values and goals, and motivating factors impacting adherence to health 
behaviors (Breckenridge & Eichler, 2013; Mann et al., 2013; Ruger, 2010).  This requires 
a theoretical or conceptual healthcare framework, such as Health Capability, that 
philosophically and practically integrates these principles.  The model requires a systems 
perspective, yet commitment to the individual, to facilitate and recognize contributions 
and perspectives from all stakeholders while respecting cost-effective and health 
promotion oriented healthcare (J. P. Sturmberg et al., 2012).   
Second, based on the established ability to represent, measure and integrate 
perceived health status by a single Likert-type subjective item, it is reasonable to consider 
the possibility of a similar approach for perceived risk.  Although typically perceived risk 
is posed in the context of specific disease or risks, one or two overall measures of 
perceived risk may serve as an effective screening or triaging measure.  For example, 
asking the patient/respondent what, in general, they consider their level of health risk to 
be as compared to others of similar age and sex, akin to previously posed survey 
questions (R. Green & Roberts, 2012a; D. J. Kaufman et al., 2012).  Secondly, a question 
needs to be posed for the individual to consider the condition for which they feel they are 
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at greatest risk, then rating that by a Likert-type item or numeric measure.  Working from 
the focus of this dissertation, the next step would be to combine these two (or three) 
values to represent perceived health status.  In combination with, and contrast to medical 
health status, these groups and variables could be examined related to the potential 
impact on self-initiated health action and behavior.  This approach has two immediately 
relevant benefits.  Clinically, there is the potential to efficiently identify the existence of 
some condition of high-risk concern to the individual, with the possibility to intervene in 
a more timely and effective manner.  From a research context, this approach may provide 
a method to test and compare the separate contributions of other subjective personal 
health/risk factors versus a combined measure.  
Third, in addition to the constructs, concepts and relationships proposed, 
examined and modified, there remains an over-riding question relevant to healthy 
persons, whether they are persons without a medical diagnosis or they are persons with a 
medical diagnosis but with perceived good to excellent health.  That question is “Why 
now?”  Why have these persons, spanning significantly different ages, diagnostic status 
and income levels chosen to pursue self-initiated genome testing when they did?  This 
author is proposing, and adding to the concept mapping, a “triggering” event (or 
threshold effect).  This would be something subjective, beyond the combined interaction 
of medical health status, perceived health status, and individual health values and goals—
that provides the impetus for action in healthy persons, or apparently non-acute or not 
medically necessitated situations.  This dimension of perceived health status is the 
intended direction of future research.  These events are proposed to include factors such 
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as the individual’s age (e.g., being the same age as the parent when diagnosed), exposure 
to a perceived health risk (e.g., with potential concern for cancer), change in health status 
(i.e., newly diagnosed medical condition), and other personal factors of which we likely 
do not know what we do not know (Costello, 2014).  In addition, concepts from other 
disciplines may be relevant to incorporate into an interdisciplinary approach to research, 
such as self-regulation and self-realization (Mann et al., 2013; Miquelon & Vallerand, 
2008), in the context of motivating factors for self-initiated pursuit of health-related 
information, as with genome testing.    
Further research is also planned to examine the other proposed subdomains 
(components) of perceived health (and/or risk), their association with and potential 
contribution to differentially influencing perceived health status, and if/how these factors 
are individually prioritized related to health values.  These issues have relevance to 
individualizing, prioritizing and effecting quality and cost-effective healthcare services 
and policy, collaborating with consumers, and promoting health at individual and public 
health level. 
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